



- (51) **International Patent Classification:**  
*A23K 1/10* (2006.01) *C12P 21/06* (2006.01)
- (21) **International Application Number:**  
PCT/EP2013/065362
- (22) **International Filing Date:**  
19 July 2013 (19.07.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
1212934.2 20 July 2012 (20.07.2012) GB
- (71) **Applicant:** DUPONT NUTRITION BIOSCIENCES  
APS [DK/DK]; Langebrogade 1, P.O. Box 17, DK-1001  
Copenhagen K (DK).
- (72) **Inventors:** YU, Shukun; Gunnar Hejdemansgatan 29, S-  
212 40 Malmö (SE). POULSEN, Charlotte, Horsmans;  
Langdalsvej 37, DK-8220 Brabrand (DK). HANSTED,  
Jon, Gade; Langelandsgade 123, DK-8000 Aarhus C  
(DK).
- (81) **Designated States** (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,

KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**


- *as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** METHOD FOR THE DEGRADATION OF KERATIN AND USE OF THE KERATIN HYDROLYSATE PRODUCED

**Fig. 1**



(57) **Abstract:** The present invention relate to a method for producing keratin hydrolysate comprising the step of: i) admixing keratin material with a protease and a non-sulphur containing surfactant, as well as keratin hydrolysate so produced and uses thereof.

## METHOD FOR THE DEGRADATION OF KERATIN AND USE OF THE KERATIN HYDROLYSATE PRODUCED

### REFERENCE TO A SEQUENCE LISTING

- 5 Attached is a sequence listing comprising SEQ ID NOs: 1-4, which are herein incorporated by reference in their entirety.

### FIELD OF THE INVENTION

- 10 The present invention relates to methods and uses of a combination a protease and a non-sulphur containing surfactant in the degradation of keratin and subsequent uses of the keratin hydrolysate produced.

### BACKGROUND OF THE INVENTION

15

- Keratin is the collective name for a family of tough proteins which are found in a number of structures. It is a protein used by numerous groups of animals as a structural element, and is a classic example of a fibrous protein. To fulfil this structural function, Keratin molecules are helical and fibrous, twisting around each other to form strands called intermediate filaments. It is thought that this makes a lot of the protein inaccessible to enzyme digestion at first instance. Additionally, keratin proteins contain a high percentage of sulfur-containing amino acids, largely cysteine, which form disulfide bridges between the individual molecules and assist in forming the fairly rigid structure of keratin. Unfortunately, the disulphide bridges also make digestion and degradation of the keratin rather difficult. There are two main types of keratin, alpha- and beta-keratins. The  $\alpha$ -keratins are mostly present in the hair (including wool), horns, nails, claws and hooves of mammals. The harder  $\beta$ -keratins are found in nails and in the scales and claws of reptiles, their shells (Testudines, such as tortoise, turtle, terrapin), and in the feathers, beaks, claws of birds and quills of porcupines.  $\beta$ -keratins are formed primarily in beta sheets, although some beta sheets are also found in  $\alpha$ -keratins.
- 20
- 25
- 30

The degradation of keratin can be of significant commercial value. One source of keratin in particular – feathers - is produced in vast quantities by the poultry industry. In 2002 approximately 49 billion chickens were utilized in the poultry industry. Poultry feathers typically contain approximately 90% protein in the form of  $\beta$ -keratin. However, keratin must be cleaved before its protein content can be digested by animals (McCasland and Richardson 1966, Poult. Sci., 45:1231-1236; Moran et al.). Degradation of feathers can therefore provide an inexpensive source of digestible protein and amino acids. Accordingly feather hydrolysate (i.e. degraded feathers) can be utilized in a numbers of ways, such as in animal feed. However, current methods of recovering this nutriment are so inefficient and costly that the vast majority of keratin waste streams are simply disposed of in landfill or via incineration, both of which can cause environmental problems and reduce the sustainability of the main commercial process (often meat production for human consumption). Unfortunately some contemporary processes for the production of keratin hydrolysate produce feather meal that is more expensive than chicken meat.

Degradation of keratin can be achieved by steam hydrolysis, chemical hydrolysis and enzyme hydrolysis. For example, steam hydrolysis is disclosed in M.J. Considine, 2000, NEW ENZYME TECHNOLOGIES FOR POULTRY BY-PRODUCTS. Proc. Aust. Poult. Sci.Sym. 2000...12, pages 163-165, ISSN No. 1034-6260). One disadvantage of steam hydrolysis is that the process can degrade heat sensitive amino acids thereby depleting the nutritional content of the resultant feather hydrolysate. Furthermore, it has been found that the feather hydrolysate produced by steam hydrolysis has a relatively low digestibility. This is clearly undesirable for the use of the feather hydrolysate in feed as the amount of protein and amino acids available to the animal is suboptimal.

Another method to degrade keratin is chemical hydrolysis. For example, acids such as hydrochloric acid, alkalis such as sodium hydroxide and oxidants such as peracid can be used to breakdown the disulfide linkages present in keratin. One disadvantage of chemical hydrolysis is that the costs of the use of such chemicals can be expensive. Another disadvantage is that the amount of amino acids may be reduced compared to enzymatic methods – see Kim *et al.* (Poultry Science, 2002,

85:95-98 – Table 2). A further serious disadvantage is that many of the agents suggested for use in chemical hydrolysis are sulphur-containing agents unsuitable for food use (for example, sodium dodecyl sulfate (SDS), dithiothreitol (DTT), mercaptoethanol, L-cysteine, sodium sulphite, ammonium sulfamate and dimethylsulfoxide (DMSO)). Such harsh chemicals may be good at disrupting disulfide bridges, but they make the resulting keratin hydrolysate unsuited for use in food or animal feed products.

A further method of degrading keratin is by enzymatic hydrolysis. A number of patents Shih *et al.* granted in the name of North Carolina State University relate to the use of *B. licheniformis* PWD-1 or a keratinase isolated from this bacterium to degrade poultry feathers see, US 4,908,220, US 4,959,311, US 5,063,311, US 5,171,682, US 5,186,961 and US 5,712,147. Enzyme degradation can be advantageous as some processes may result in more digestible protein and amino acids being present compared with the use of steam hydrolysis or chemical hydrolysis.

However, as disclosed in Cai *et al.* (J. Zhejiang Univ. Sci. B 2008 9(9):713-720) the use of a protease (such as keratinase) alone may be very inefficient in the degradation of keratin. Cai *et al.* discloses that sulphur-containing chemicals such as SDS, ammonium sulfatate and DMSO stimulated feather meal hydrolysis due to reactions caused by the sulphur-containing chemicals. However, one disadvantage with the use of sulphur-containing chemicals is that high levels of sulfites can provide potentially detrimental side-effects. For example, high levels of sulfite are linked with the aggravation of asthma in certain people and can be hazardous if used at high temperatures in industrial processes.

Therefore, it is desirable to provide a method for degrading keratin which provides a desirable balance with regard to efficiency, cost-effectiveness and nutritional content of the resultant hydrolysate. For example, it is desirable to provide a method of degrading keratin which results in a good source of digestible protein and amino acids whilst minimizing cost and/or whilst reducing the amount of sulphur containing chemicals utilised.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Fig. 1** shows the degradation of chicken feathers following reaction with (from left to right): 20 mg sodium bisulphite (K2), 150 µl Protex 30L (E0); 150 µl Protex 30L and 20mg sodium sulphite (E1 – 2 test tubes); and 150 µl Protex 30L and 20mg sodium bisulphite (E2 – 2 test tubes).

**Fig. 2** shows the degradation of chicken feathers following reaction with protease (Protex 30L) in the presence or absence of Grinsted® SSL P 55 VEG K-A (E481, Sodium stearoyl lactate) and sodium sulphite. All tubes contain Protex 30L, in addition from left to right: test tubes 1.0 and 1.1 contain 20mg Grinsted® SSL and 20 mg Sodium sulphite; test tube 1.2 contains 20 mg sodium sulphite and test tube 1.3 contains 20 mg Grinsted® SSL .

**Fig. 3** shows the amount of degradation of chicken feathers following reaction with protease (Protex 30L) in the presence or absence of Panodan® 517 KOSHER (E472e, diacetyltartaric acid esters of mono- and diglycerides) and Sodium sulphite. All tubes contain Protex 30L, in addition from left to right: test tubes 2.0 and 2.1 contain 20 mg Panodan® 517 and 20 mg Sodium sulphite, test tube 2.2. contains 20 mg Sodium sulphite and test tube 2.3 contains 20 mg Panodan® 517.

**Fig. 4** shows the keratin hydrolysis measured by absorbance following reaction of keratin material under various concentrations of protease Protex P.

**Fig. 5** shows the effects of non-sulphur containing surfactants on the hydrolysis of feather in combination with protease, expressed as keratinolytic units. All five non-sulphur containing surfactants were added to reach a final concentration of 0,1 % w/v along with 1 % v/v protease (Protex P). Protex P: reaction without a non-sulphur containing surfactant present. Control: reaction with neither non-sulphur containing surfactant nor protease present. Bars represent standard deviation. Means with the letters a-f are significantly different according to Holm-Sidak pairwise comparison at  $P=0.05$ .

**Fig. 6** shows the effects of non-sulphur containing surfactants only on the hydrolysis of feather, expressed as keratinolytic units. All five non-sulphur containing surfactants were added to reach a final concentration of 0,1 % w/v. Control: reaction without  
5 containing surfactants present. Bars represent standard deviation. Means with the letters a-c are significantly different according to Holm-Sidak pairwise comparison at  $P=0.05$ .

**Fig. 7** shows the synergistic effect of non-sulphur containing surfactants in  
10 combination with protease. Calculated values generated by addition of data from the experiments with protease alone, and with non-sulphur containing surfactants alone.  
\* indicates statistical significant difference between the observed and calculated value according to t-test at  $P=0,05$  performed using SigmaPlot 11.0 software.

15 **Fig. 8** shows Sequence ID NO 1 Protex P

**Fig. 9** shows Sequence ID NO 2 Protex 6L

**Fig. 10** shows Sequence ID NO 3

20 **Fig. 11** shows Sequence ID NO 4

## SUMMARY OF THE INVENTION

A seminal finding of the present invention is that non-sulphur containing surfactants can stimulate keratin degradation by proteases. This finding is particularly surprising  
5 as prior to the present invention it was generally believed that the presence of sulphur or the use of a reducing agent was key in stimulating keratin hydrolysis by proteases.

For the first time the present inventors have shown that non-sulphur containing  
10 surfactants (such as sodium stearyl-2-lactylate and diacetyl tartartic acid esters of mono and diglycerides of fatty acids) enhance the degradation and/or solubilisation of keratin by proteases. This surprising finding allows keratin to be degraded and/or solubilized to provide, and/or keratin hydrolysate to be produced which has, a good source of digestible protein and amino acids. Advantageously, the use of a non-  
15 sulphur containing surfactant in the enzymatic degradation of keratin may result in one or more of the following advantageous effects: i) a quicker process to achieve a desired level of degradation or a desired level of digestible protein and/or amino acids; ii) improved cost efficiencies in obtaining keratin hydrolysate with a desired level of digestible protein and/or source of amino acids; and/or iii) a reduction in the  
20 amount of the amount of sulphur containing chemicals utilized in the process.

## STATEMENTS OF THE INVENTION

In one aspect, the present invention provides a method of producing keratin  
25 hydrolysate comprising the step of i) admixing keratin material with a protease and a non-sulphur containing surfactant, optionally in a closed system or under controlled oxygen levels.

In another aspect, the present invention provides a method of degrading keratin wherein a keratin material is admixed with a protease and a non-sulphur containing  
30 surfactant.

In a further aspect, the present invention provides a method of producing animal feed comprising admixing keratin hydrolysate produced by a method of the present invention with one or more animal feed constituents.

- 5 In a further aspect, the present invention provides the use of a composition comprising a non-sulphur containing surfactant to stimulate enzymatic keratin degradation. Suitably the composition comprising a non-sulphur containing surfactant may optionally comprise a protease. Suitably, the composition may be a pharmaceutical composition or a cosmetic composition.

10

In another aspect, the present invention provides use of keratin hydrolysate produced by the method of the present invention in feed.

- 15 In another aspect, the present invention provides a method of producing animal feed comprising admixing keratin hydrolysate produced by a method of the present invention.

In a further aspect, the present invention provides a feed additive composition comprising the keratin hydrolysate of the present invention.

- 20 In another aspect, the present invention provides a feed comprising the keratin hydrolysate of the present invention.

These and other aspects of the present invention are described in more detail in the detailed disclosure of the preferred embodiments of the invention below.

25

#### DETAILED DISCLOSURE OF THE PREFERRED EMBODIMENTS OF THE INVENTION

- 30 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, *et al.*, DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial,



NY (1991) provide one of skill with a general dictionary of many of the terms used in this disclosure.

This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

Before the exemplary embodiments are described in more detail, it is to understand that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a protease" includes a plurality of such enzymes and reference to "the feed" includes reference to one or more feeds and equivalent thereof known to those skilled in the art, and so forth.

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

## METHOD

In one aspect, the present invention relates to a method of degrading keratin or producing keratin hydrolysate comprising admixing a keratin material with a protease and a non-sulphur containing surfactant.

The term "keratin hydrolysate" as used herein refers to the resultant product following the hydrolysis of a keratin material by e.g. a protease.

The admixture may occur in a vessel or reactor. In one embodiment, the vessel or reactor is a free-fall vessel or reactor. Examples of free-fall vessels include drum mixers and tumble mixers.

Suitably keratin material, one or more proteases and one or more surfactants may optionally be admixed (simultaneously or sequentially) with one or more further components.

The keratin material, protease and non-sulphur containing surfactant are admixed until a desired degree of degradation of the keratin material has occurred (e.g. until the digestibility of keratin material is increased, thereby enriching the concentration of digestible proteins and peptides therein). A person of ordinary skill in the art will readily understand that the optimal time period used will depend on a number of

factors such as the temperature and pH in relation to the optimal pH and optimal temperature of the protease used; the degree of cross-linking present in the keratin material to be degraded; whether other components such as reducing agents, chemical oxidants, acids or alkalis are used in the process and the amount ratio of protease to keratin material for example.

In one embodiment, the keratin material, protease and non-sulphur containing surfactant may be admixed for about 30 minutes to about 48 hours. Suitably, the keratin material and protease may be admixed from about 1 hour to about 42 hours; or from about 2 hours to about 36 hours; or from about 3 hours to about 30 hours; or from about 4 hours to about 24 hours; or from about 5 to about 18 hours.

In one embodiment, the keratin material, protease and non-sulphur containing surfactant may be admixed for about 30 minutes to about 16 hours; or from about 30 minutes to about 14 hours; or from about 1 hour to about 12 hours; or from about 1.5 hours to about 10 hours; or from about 2 hours to about 8 hours; or from about 3 to about 7 hours.

Suitably the keratin material, protease and non-sulphur containing surfactant may be admixed for at least 30 minutes; or at least 45 minutes; or at least 1 hour; or at least 1.5 hours; or at least 2 hours; or at least 2.5 hours; or at least 3 hours; or at least 3.5 hours; or at least 4 hours; or at least 4.5 hours ;or at least 5 hours; or at least 5.5 hours; or at least 6 hours; or at least 7 hours; or at least 8 hours; or at least 9 hours; or at least 10 hours.

In one embodiment, the keratin material, protease and non-sulphur containing surfactant is admixed for at least 2 hours.

Suitably, the keratin material, protease and non-sulphur containing surfactant may be admixed for less than 16 hours, less than 15.5 hours, less than 15 hours, less than 14.5 hours, less than 14 hours or less than 13 hours.

In one embodiment, the keratin and material, protease and non-sulphur containing surfactant may be admixed for less than 16 hours.

5 In one embodiment, the keratin and material, protease and non-sulphur containing surfactant may be admixed for less than 13 hours

In one embodiment, the keratin and material, protease and non-sulphur containing surfactant may be admixed for about 1.5 to about 10 hours.

10 In one embodiment, the keratin material, protease and non-sulphur containing surfactant may be admixed until at least 50% by weight of the keratin material is degraded. Optionally, the keratin material, protease and non-sulphur containing surfactant may be admixed until at least 55% (suitably at least 60% or at least 70% or at least 80% or at least 90% or 100%) by weight of the keratin material is degraded.

15 Degraded or degradation of feather material by 100% may be defined by the complete detachment of vanes, barbs and after feather from the rachis and hollow shaft; and the fragmentation of the rachis and hollow shaft such that feather meal is produced in one single step.

20 In one embodiment, the keratin material (e.g. wet feathers) may be processed (e.g. mechanically) into small pieces. The keratin material may be added to a vessel (e.g. at ambient temperature) and heated (for example to 50-80°C) with the addition of a protease, a non-sulphur containing surfactant and optionally a chemical and/or a reducing agent (e.g. sulfite). The vessel may be a closed reactor optionally with  
25 reduced airspace to control oxygen levels. The keratin material and protease are reacted for a suitable time (e.g. for 30 to 48 hours). The vessel may be rotated or the vessel contents may be admixed (e.g. using a propeller at 1-200 rpm). During the reaction process the mixing may cause some oxygen to be continually introduced into to the reaction liquid. Accordingly, the airspace of the vessel may  
30 advantageously have lower level of oxygen (e.g. through the use of stream to expel air out of the reactor). The resultant keratin material (e.g. feather meal) may be dried and may be used as feed components. Suitably, such a process has the advantages of reducing energy associated with grinding the keratin material and the utilisation of

particular high temperatures (e.g. 120°C) which can lead to the damage of certain amino acids.

Suitably the pH during the reaction is within the working range of the protease used.

- 5 It is a matter of routine to a person of ordinary skill in the art to determine the optimal working range of the protease used and to add buffer to adjust the reaction solution to an appropriate pH. For example, the working pH range of the protease Protex 30L (available from DuPont Industrial Biosciences ApS) may be from about 5.5 to about 12. When Protex 30 L is used as the protease, the pH during the admixing step may  
10 be from about 5.5 to about 12. Suitably, the pH range may be from about 7 to about 11, or from about 8 to about 10. Preferably, when Protex 30L is used the pH is about pH 9.

- In one embodiment, the pH used is a pH at about the optimal pH for the protease  
15 used. For example, the pH may be +/- about 1 pH of the optimal pH of the protease used (e.g. a pH of about 8 to about 10 for Protex 30L). Suitably, the pH may be +/- about 0.5 pH of the optimal pH of the protease used.

In another embodiment, the pH used is the optimal pH of the protease.

20

Suitably the temperature during the reaction is adjusted to be within the working range of the protease used. It is a matter of routine to a person of ordinary skill in the art to determine the optimal working range of the protease used and to carry out the reaction at a desired temperature. For example, the working range of the protease  
25 Protex 30L may be from about 30°C to about 80°C. When Protex 30 L is used as the protease, the temperature during the admixing step may be from about 30°C to about 80°C. Suitably, the temperature may be from about 40°C to about 80°C, or from about 50°C to about 80°C. Suitably, the temperature may be or from about 60°C to about 80°C. Preferably, when Protex 30L is used the temperature is about 70°C.

30

Suitably the temperature used may be + and/or – 15°C; or + and/or – 10°C; or + and/or – 5°C; or + and/or – 4°C; or + and/or – 3°C; or + and/or – 2°C; or + and/or –

1°C of the optimal temperature of the protease used. Preferably the temperature used is about the optimal working temperature of the protease used.

5 In one embodiment, the temperature used is + and/or – 10°C of the optimal temperature of the protease used.

In another embodiment, the temperature used is + and/or – 5°C of the optimal temperature of the protease used.

10 In one embodiment, more than one enzyme may be present in the admixing step. Suitably, the temperature, pH and other reaction conditions used may then be selected to be within the working ranges of the enzymes used. Suitably, the enzymes used (e.g. more than one protease and/or other additional enzymes) are selected which have overlapping working ranges. Preferably, the enzymes are selected to  
15 have compatible, preferably similar working ranges.

Suitably, prior to admixing the keratin material with the protease and/or non-sulphur containing surfactant the feather may be sterilised e.g. to reduce and/or prevent bacterial contamination. This sterilization step may be carried out by any available  
20 means. For example, fumigation could be achieved by contacting the keratin material with formalin or ethylene oxide gas. Alternatively and/or additionally, steam sterilisation could be achieved by steaming under pressure. Suitably steam sterilisation may be preferable to aid subsequent enzymatic degradation of the keratin material.

25

In one embodiment, the keratin material may be pre-treated with steam to expel air from the vessel, to heat the vessel to a temperature of 40 to 121°C (preferably 50-80°C) and/or to sterilize the keratin material. Suitably, protease and/or sulfite may be admixed with the keratin material before or after such steam treatment.

30

In one embodiment, the keratin material is steam sterilised prior to the reaction step. Suitably, the steam sterilisation comprises a step of contacting the keratin to steam for a time and at a temperature sufficient to facilitate the subsequent enzymatic

hydrolysis thereof, even if this steam treatment step does not accomplish a complete sterilization of the keratin material. Suitably, the steam sterilisation may comprise contacting keratin material to steam under pressure, in an enclosed chamber, at 120 to 125 °C for at least 2 minutes, or at least 5 minutes, or at least 10 minutes, or at least 15 minutes, or at least 20 minutes. Suitably, the time and temperature of steam treatment may be less than those employed in commercial steam hydrolysis processes, which employ treatment times of 35 minutes or more at steam pressures of about 35 p.s.i. or more.

10 In one embodiment of the present invention, the methods of the present invention may comprise a chemical hydrolysis step which may occur prior to, during and/or after the reaction step with protease and/or non-sulphur-containing surfactant.

15 In one embodiment of the present invention, the methods of the present invention may comprise a chemical hydrolysis step which may occur prior to and/or during the reaction step with protease and/or non-sulphur-containing surfactant.

20 In one embodiment of the present invention, the methods of the present invention may comprise a chemical hydrolysis step which may occur after the reaction step with protease and/or non-sulphur-containing surfactant.

25 In one embodiment, suitably the acid or alkali used in the chemical hydrolysis may provide the means for pH adjustment to the optimal working conditions of the protease.

In one embodiment, chemical hydrolysis may occur after the reaction step with a protease.

30 The process of the present invention may be carried out as a batch, fed-batch or continuous process.

In one embodiment, the process of the present invention may be carried out in a batch process. Advantageously, a batch process is more easily adapted for controlling oxygen levels.

- 5 In one embodiment, the feather hydrolysate produced by the method of the present invention may be in the form of a precipitate. Suitably, particulate matter greater than 1.0 cm (suitably greater than 0.1 cm) is recycled for pre-treatment or hydrolysis.

10 In one embodiment, the feather hydrolysate produced by the method of the present invention may be in the form of a solution.

### SURFACTANT

15 The method and uses of the present invention utilise a non-sulphur containing surfactant.

20 In one embodiment, the term “surfactant” as used herein refers to a substance which reduces the surface tension of a liquid in which it is dissolved. For example, the surfactant may reduce the surface tension of water. The surfactant may preferably act as a detergent, wetting agent, emulsifier or dispersant. Suitably, the surfactant may be amphiphilic (i.e. may contain both hydrophobic and hydrophilic groups).

25 In another embodiment, the “surfactant” may be an “emulsifier”. The term “emulsifier” as used herein refers to substances which stabilise an emulsion by increasing its kinetic stability.

Preferably, the surfactant (e.g. emulsifier) used is not toxic to animals and/or humans.

30 Preferably the surfactant is selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20; Tween 80; lecithin; polyoxyethylene stearate; polyoxyethylene sorbitan monolaurate; polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitan monopalmitate; polyoxyethylene sorbitan monostearate;



polyoxyethylene sorbitan tristearate; ammonium phosphatides; sodium, potassium or calcium salts of fatty acids; magnesium salts of fatty acids; acetic acid esters of mono- and diglycerides of fatty acids; lactic acid esters of mono- and diglycerides of fatty acids; citric acid esters of mono- and diglycerides of fatty acids; mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides; polyglycerol esters of fatty acids; polyglycerol polyricinoleate; propane-1,2-diol esters of fatty acids; thermally oxidised soya bean oil interacted with mono- and diglycerides of fatty acids; sodium stearyl-2-lactylate; calcium stearyl-2-lactylate; sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan monooleate and sorbitan monopalmitate.

In one embodiment, the surfactant is selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20 and Tween 80. Preferably, the surfactant is sodium decanoate.

15

In one embodiment, the surfactant is an emulsifier selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20; Tween 80; lecithin; polyoxyethylene stearate; polyoxyethylene sorbitan monolaurate; polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitan monopalmitate; polyoxyethylene sorbitan monostearate; polyoxyethylene sorbitan tristearate; ammonium phosphatides; sodium, potassium or calcium salts of fatty acids; magnesium salts of fatty acids; acetic acid esters of mono- and diglycerides of fatty acids; lactic acid esters of mono- and diglycerides of fatty acids; citric acid esters of mono- and diglycerides of fatty acids; mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides; polyglycerol esters of fatty acids; polyglycerol polyricinoleate; propane-1,2-diol esters of fatty acids; thermally oxidised soya bean oil interacted with mono- and diglycerides of fatty acids; sodium stearyl-2-lactylate; calcium stearyl-2-lactylate; sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan monooleate and sorbitan monopalmitate. Advantageously, such surfactants are emulsifiers that are currently used in the food industry and are generally recognised as safe for use in food.

In one embodiment, only one surfactant is used in combination with a protease in the methods and uses of the present invention. In another embodiment, any combinations of two or more surfactants are used. For example any combination of 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 surfactants may be used.

5

The optimal amount of surfactant to be used can be readily determined by a person of ordinary skill in the art.

10

In one embodiment, the amount of surfactant used may be in the range of about 0.01% w/v to about 1% w/v. Preferably, the amount of surfactant may be in the range of about 0.05 – 0.9 %w/v.

15

Suitably, the amount of surfactant used may be greater than or equal to 0.01% w/v keratin material. Preferably, the amount of surfactant used may be greater than or equal to 0.02% w/v; or 0.05% w/v or 0.1% w/v keratin material.

20

Suitably, the amount of surfactant used may be less than or equal to 1% w/v keratin material. Preferably, the amount of surfactant used may be less than or equal to 0.9% w/v; or 0.8% w/v or 0.5% w/v keratin material.

25

In one embodiment, the amount of surfactant used may be in the range of about 0.1 g/Kg to about keratin material 10 g/Kg keratin material (e.g. feathers). Suitably, the amount of surfactant used may be in the range of about 0.5 g/Kg to about keratin material 5 g/Kg keratin material (e.g. feathers).

30

Suitably, the amount of surfactant used may be greater than or equal to 0.1 g/Kg keratin material. Preferably, the amount of surfactant used may be greater than or equal to 0.5 g/Kg; or 1 g/Kg; or 2 g/Kg keratin material.

Suitably, the amount of surfactant used may be less than or equal to 10 g/Kg keratin material. Preferably, the amount of surfactant used may be less than or equal to 8 g/Kg; or 5 g/Kg or 3 g/Kg keratin material.

In one embodiment, the ratio of surfactant to keratin material may be in the range of about 1:100 to about 1:10,000. Preferably the ratio of surfactant to keratin material may be in the range of about 1:500 to about 1:5,000.

- 5 Suitably, the ratio of surfactant to keratin material may be greater than 1:10,000.

Suitably, the ratio of surfactant to keratin material may be less than 1:100.

- 10 In one embodiment, the surfactant is a non-sulphur containing surfactant. Without wishing to be bound by theory, it is believed that a surfactant may work by opening up the hydrophobic keratin material in the solution thereby allowing the enzyme better access to the structure to carry out the hydrolysis. Alternatively the surfactant may help to remove hydrolyzed protein from the surface of the feather to solution so that the underlying surface of the feather is exposed to proteolysis.

15

- In one embodiment, a non-sulphur containing surfactant may be a surfactant for use in the methods and uses of the present invention if in a process for degrading a keratin material (e.g. feathers) there is an increase in the amount of soluble protein present in solution at the end of the process compared to the amount of soluble protein present in solution for a control method in which the non-sulphur containing surfactant was not used. Suitably, the increase in soluble protein may be measured by an increase in absorbance at 215-280 nm.
- 20

### KERATIN MATERIAL

25

Keratin is a fibrous structural protein found in feather, hair, fur, hooves, nails, wool, claws and scales. Keratins can be divided into two separate groups  $\alpha$ -keratins and  $\beta$ -keratins. The  $\beta$ -keratins are generally harder than  $\alpha$ -keratins as they contain more cysteine linkages.

30

The keratin material for use in the methods and uses of the present invention can be any substance which comprises keratin. Suitably, the keratin material may comprise feathers, hair, fur, hooves, nails and wool.

In one embodiment, the keratin material comprises  $\beta$ -keratin.  $\beta$ -keratins may be found in nails and claws of reptile, shells of Testudines and in the feathers beaks and claws of birds and porcupines. Suitably, the keratin material may be feathers, preferably poultry feathers, preferably chicken feathers.

5

In one embodiment, the keratin material comprises  $\alpha$ -keratin.  $\alpha$ -keratins may be found in the hair (including wool), horns, nails, claws and hooves of mammals. Suitably, the keratin material may be hair, horns or hooves.

10 In one embodiment, the keratin material comprises feathers, hair, horns, hooves or wool. Suitably, the keratin material may be feathers, hair, horns, hooves or wool.

In one embodiment, at least 5 g of keratin material is used in the processes and uses of the present invention. Suitably, at least 50g, preferably at least 100g, preferably at  
15 least 500g keratin material is used in the processes and uses of the present invention.

In one embodiment, at least 1 kg of keratin material is used, preferably at least 2 kg, or at least 10kg, or at least 20kg, or at least 30kg keratin material is used.

20

### PROTEASE

The term "protease" as used herein is synonymous with peptidase or proteinase.

25 The protease for use in the present invention may be a subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.x.x). Suitably, a protease for use in the present invention may be an Protease endopeptidase K (EC 3.4.2.1.64), an endopeptidase Arg-C, an endoprotease Gluc-C (EC 3.4.21.19), an enterokinase (EC 3.4.21.9), a collagenase  
30 (EC 3.4.24.3), a thermolysin (EC 3.4.24.27), a trypsin (EC 3.4.21.4), a chymotrypsin (EC 3.4.21.1), a pepsin (EC 3.4.23.1), an aspergillopepsin (EC 3.4.23.18), a sedolisin (EC 3.4.21.100), or a dipeptidyl peptidase (EC 3.4.14.1).

Preferably the protease in accordance with the present invention is a subtilisin, a serine protease, a metalloprotease, an acid protease, a neutral protease or a keratinase.

5 Suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable. The protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus* sp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309  
10 (see, e.g., U.S. Patent No. 6,287,841), subtilisin 147, and subtilisin 168 (see, e.g., WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and *Fusarium* proteases (see, e.g., WO 89/06270 and WO 94/25583). Examples of useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/20115. All of which are incorporated herein by  
15 reference.

The terms "wild type protease enzyme" or "wild type" in accordance with the invention describe a protease enzyme with an amino acid sequence found in nature.

20 The terms "protease enzyme variant", "protease variant" or "variant" in accordance with the invention describe a protease enzyme with an amino acid sequence derived from the amino acid sequence of a parent protease but differing by one or more amino acid substitutions, insertions, and/or deletions, which together are referred to as "mutations". It is envisaged that a protease enzyme variant may also be a parent  
25 protease enzyme for further rounds of methods of preparing protease variants such as molecular evolution.

The term "homologous polypeptide(s)", according to the present invention, described also as "homologues" herein, describe polypeptides, preferably protease enzymes  
30 (i.e. "homologous protease " or "homologous enzymes") with a sequence identity of more than 75% compared to a first polypeptides/proteases/enzymes amino acid sequence, preferably has at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology.

The term "functional equivalent thereof" means that the enzyme has to have about the same functional characteristics as that of the protease detailed herein. The term "modified form" or "variant" means that the enzyme has been modified from its original form but retains the same enzymatic functional characteristics. In particular, the terms "variant" or "modified form" encompass protease enzymes with an amino acid sequence derived from the amino acid sequence of the parent/wild-type protease and having one or more amino acid substitutions, insertions, and/or deletions, which together are referred to as mutations. Modified forms or variants may display altered enzyme characteristics compared to the parent enzyme. Preferably, modified forms or variants have one or more of the following enhanced phenotypes: increased thermostability and/or; an increased proteolytic (for example pepsin) stability and/or; an increased specific activity and/or; broader substrate specificity and/or; an activity over a broader pH range. The term "functional" or "effective" fragment means a fragment or portion of the protease that retains about the same enzymatic function or effect.

As used herein the term "thermostable" relates to the ability of the enzyme to retain activity after exposure to elevated temperatures.

As used herein the term "pH stable" relates to the ability of the enzyme to retain activity over a wide range of pH's.

In one preferred embodiment the protease for use in the present invention may be one or more of the proteases in one or more of the commercial products below:

<b>Commercial product®</b>	<b>Company</b>	<b>Protease type</b>	<b>Protease source</b>
Protex 30L™	Genencor/DuPont	Serine protease*	<i>B. subtilis</i>
Protex 6L™	Genencor/DuPont	Serine protease*	<i>B. amyloliquefaciens</i>
Purafect 4000L™	Genencor/DuPont	Serine protease*	
FNA™	Genencor/DuPont	Serine protease*	<i>B. amyloliquefaciens</i>
Properase 1600L™	Genencor/DuPont	Serine protease*	<i>B. alcalophilus</i>
Protex P™	Genencor/DuPont	subtilisin	
Esperase 8.0L	Novozymes	protease	<i>Bacillus</i> sp.
Everlase 16.0™		subtilisin	<i>Bacillus</i> sp.
Alcalase 2.4™	Novozymes	subtilisin	<i>Bacillus</i> sp.
Neutrase 0.8L™	Novozymes	protease	<i>B. amyloliquefaciens</i>
Allzyme FD™	Alltech	Serine protease*	<i>Aspergillus niger</i>
Arazyme One-Q™	Insect Biotech Co.	metalloprotease	<i>Serratia proteamaculans</i> HY-3
Savinase™	Novozymes	subtilisin	<i>Bacillus</i> sp.
Ronozyme ProAct	DSM/Novozymes	Alkaline serine protease	<i>Nocardiopsis prasina</i> gene expressed in <i>Bacillus licheniformis</i>
Versazyme/Cibenza DP100	Novus	Keratinase	<i>Bacillus licheniformis</i>

- 5 Additionally or in the alternative the protease may be comprised in one or more of the following commercially available products: Kannase,<sup>TM</sup>, NovoCarne Tender<sup>TM</sup>, and Novozym 37020, Novo-Pro D<sup>TM</sup> (all available from Novozymes); BioSorb-ACDP<sup>TM</sup> (Noor Creations, India); or Angel<sup>TM</sup> Acid Protease (Angel Yeast Co, Ltd., China).

Suitably, the protease may be a protease from *Bacillus* (such as *Bacillus subtilis*, *Bacillus amyloliquefaciens*, *B. alcalophilus* and *B. licheniformis*), *Trichoderma*, *Nocardiosis*, *Serratia* or *Aspergillus*.

- 5 In one embodiment, the protease is from *Bacillus*. Suitably, the protease may be from the species *Bacillus subtilis*, *Bacillus amyloliquefaciens*, *B. alcalophilus*, *B. lentus* and *B. licheniformis*. In one embodiment, the protease is from the species *Bacillus subtilis*.

## 10 **Amino acid sequences**

In one embodiment, the protease has the amino acid sequence ID No.1.

In one embodiment, the protease has the amino acid sequence ID No.2.

15

The scope of the present invention also encompasses amino acid sequences of enzymes having the specific properties as defined herein.

20

As used herein, the term “amino acid sequence” is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”.

25

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

30

The protein encompassed in the present invention may be used in conjunction with other proteins, particularly enzymes. Thus the present invention also covers a combination of proteins wherein the combination comprises the protease of the present invention and another enzyme, which may be another protease according to the present invention.



Preferably the amino acid sequence when relating to and when encompassed by the *per se* scope of the present invention is not a native enzyme. In this regard, the term "native enzyme" means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence.

5

### **Sequence identity or sequence homology**

The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

15

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

20 In the present context, an homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

25 In the present context, an homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues

30

having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of  
5 readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

Percentage homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence  
10 is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an “ungapped” alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration  
15 that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in percentage homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible  
20 insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.

However, these more complex methods assign “gap penalties” to each gap that  
25 occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap.  
30 This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons.

Calculation of maximum percentage homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the the Vector NTI (Invitrogen Corp.). Examples of software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60).

Although the final percentage homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI package.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably percentage sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

30

Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used for pairwise alignment:

27

FOR BLAST	
GAP OPEN	0
GAP EXTENSION	0

FOR CLUSTAL	DNA	PROTEIN	
WORD SIZE	2	1	K triple
GAP PENALTY	15	10	
GAP EXTENSION	6.66	0.1	

In one embodiment, CLUSTAL may be used with the gap penalty and gap extension set as defined above.

5

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

10

Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

## 15 **Variants/homologues/derivatives**

The present invention also encompasses the use of variants, homologues and derivatives of any amino acid sequence of a protein or of any nucleotide sequence encoding such a protein.

20

Here, the term “homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term “homology” can be equated with “identity”.

25

In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 80, 85 or 90% identical, preferably at least 95,

96, 97, 98 or 99% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

In the present context, an homologous sequence is taken to include a nucleotide sequence which may be at least 75, 80, 85 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to a nucleotide sequence encoding an enzyme of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate percentage homology between two or more sequences.

Percentage homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in percentage homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This

is achieved by inserting “gaps” in the sequence alignment to try to maximise local homology.

However, these more complex methods assign “gap penalties” to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. “Affine gap costs” are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap.

This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum percentage homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux *et al* 1984 *Nuc. Acids Research* 12 p387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *Short Protocols in Molecular Biology*, 4<sup>th</sup> Ed – Chapter 18), FASTA (Altschul *et al.*, 1990 *J. Mol. Biol.* 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999, *Short Protocols in Molecular Biology*, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see *FEMS Microbiol Lett* 1999 **174**(2): 247-50; *FEMS Microbiol Lett* 1999 **177**(1): 187-8 and [tatiana@ncbi.nlm.nih.gov](mailto:tatiana@ncbi.nlm.nih.gov)).

Although the final percentage homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison.

Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

- Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS<sup>TM</sup> (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), *Gene* **73**(1), 237-244).

Once the software has produced an optimal alignment, it is possible to calculate percentage homology, preferably percentage sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

- Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
	Polar – charged	D E
		K R
AROMATIC		H F W Y

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

Replacements may also be made by unnatural amino acids include; alpha\* and alpha-disubstituted\* amino acids, N-alkyl amino acids\*, lactic acid\*, halide derivatives of natural amino acids such as trifluorotyrosine\*, p-Cl-phenylalanine\*, p-Br-phenylalanine\*, p-I-phenylalanine\*, L-allyl-glycine\*,  $\beta$ -alanine\*, L- $\alpha$ -amino butyric acid\*, L- $\gamma$ -amino butyric acid\*, L- $\alpha$ -amino isobutyric acid\*, L- $\epsilon$ -amino caproic acid<sup>#</sup>, 7-amino heptanoic acid\*, L-methionine sulfone<sup>#\*</sup>, L-norleucine\*, L-norvaline\*, p-nitro-L-phenylalanine\*, L-hydroxyproline<sup>#</sup>, L-thioprolin\*, methyl derivatives of phenylalanine (Phe) such as 4-methyl-Phe\*, pentamethyl-Phe\*, L-Phe (4-amino)<sup>#</sup>, L-Tyr (methyl)\*, L-Phe (4-isopropyl)\*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)\*, L-diaminopropionic acid<sup>#</sup> and L-Phe (4-benzyl)\*. The notation \* has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #\* indicates amphipathic characteristics.



Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or  $\beta$ -alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the  $\alpha$ -carbon substituent group is on the residue's nitrogen atom rather than the  $\alpha$ -carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ *et al.*, *PNAS* (1992) **89**(20), 9367-9371 and Horwell DC, *Trends Biotechnol.* (1995) **13**(4), 132-134.

In one aspect, preferably any of the protease sequences according to the present invention is in an isolated form. The term "isolated" means that the protease sequence is at least substantially free from at least one other component with which the protease sequence is naturally associated in nature and as found in nature. The protease sequence of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.

In one aspect, preferably the protease sequence according to the present invention is in a purified form. The term "purified" means that the a given component is present at a high level. The component is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.

The present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995

and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D. M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

In one embodiment, the protease is encoded by the nucleic acid sequence ID No.3.

In one embodiment, the protease is encoded by the nucleic acid sequence ID No.4.

The scope of the present invention encompasses nucleotide sequences encoding proteins having the specific properties as defined herein. The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti-sense strand. The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention.

In a preferred embodiment, the nucleotide sequence when relating to and when encompassed by the *per se* scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. However, the amino acid sequence encompassed by scope the present invention can be isolated and/or purified post

expression of a nucleotide sequence in its native organism. Preferably, however, the amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

Typically, the nucleotide sequence encompassed by the scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH *et al.*, (1980) *Nuc Acids Res Symp Ser* 215-23 and Horn T *et al.*, (1980) *Nuc Acids Res Symp Ser* 225-232).

### **Preparation of the nucleotide sequence**

A nucleotide sequence encoding either a protein which has the specific properties as defined herein or a protein which is suitable for modification may be identified and/or isolated and/or purified from any cell or organism producing said protein. Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PCR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.

By way of further example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the enzyme. If the amino acid sequence of the enzyme is known, labelled oligonucleotide probes may be synthesised and used to identify enzyme-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify enzyme-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

Alternatively, enzyme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar plates containing a substrate for enzyme (i.e. maltose), thereby allowing clones expressing the enzyme to be identified.

In a yet further alternative, the nucleotide sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. *et al.*, (1981) *Tetrahedron Letters* **22**, p 1859-1869, or the method described by Matthes *et al.*, (1984) *EMBO J.* **3**, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K *et al.*, (*Science* (1988) **239**, pp 487-491).

The nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of nucleotide sequences of the present invention.

The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or

derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.

- 5 Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other homologues may be obtained and such
- 10 homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high
- 15 stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.

Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and

20 homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

25

The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

- 30 Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be

desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

## Hybridisation

The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto.

The term “hybridisation” as used herein shall include “the process by which a strand of nucleic acid joins with a complementary strand through base pairing” as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.

5

The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.

10 The term “variant” also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.

Preferably, the term “variant” encompasses sequences that are complementary to  
15 sequences that are capable of hybridising under stringent conditions (e.g. 50°C and 0.2xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub>citrate pH 7.0}) to the nucleotide sequences presented herein.

More preferably, the term “variant” encompasses sequences that are complementary  
20 to sequences that are capable of hybridising under high stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub>citrate pH 7.0}) to the nucleotide sequences presented herein.

The present invention also relates to nucleotide sequences that can hybridise to the  
25 nucleotide sequences of the present invention (including complementary sequences of those presented herein).

The present invention also relates to nucleotide sequences that are complementary  
to sequences that can hybridise to the nucleotide sequences of the present invention  
30 (including complementary sequences of those presented herein).

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency.

- 5 In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).

- 10 In a more preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g. 65°C and 0.1xSSC).

### **Molecular evolution**

- 15 As a non-limiting example, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded polypeptide by various means.

- 20 In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wildtype or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide. The production of new preferred variants can be achieved by various methods well established in the art, for example the Error Threshold Mutagenesis (WO 92/18645), oligonucleotide mediated random mutagenesis (US 5,723, 323), DNA shuffling (US 5,605,793), exo-mediated gene assembly WO00/58517. The application of these and similar random directed molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-
- 25 30 predictable but beneficial mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following:



optimised expression and/or activity in a host cell or in vitro,  
increased enzymatic activity, altered substrate and/or product specificity,  
increased or decreased enzymatic or structural stability, altered enzymatic  
activity/specificity in preferred environmental conditions, e.g.

5 temperature, pH, substrate

### Site-directed mutagenesis

Once a protein-encoding nucleotide sequence has been isolated, or a putative  
10 protein-encoding nucleotide sequence has been identified, it may be desirable to  
mutate the sequence in order to prepare a protein of the present invention.

Mutations may be introduced using synthetic oligonucleotides. These  
oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

15

A suitable method is disclosed in Morinaga *et al.*, (*Biotechnology* (1984) **2**, p646-  
649). Another method of introducing mutations into enzyme-encoding nucleotide  
sequences is described in Nelson and Long (*Analytical Biochemistry* (1989), **180**, p  
147-151).

20

### Recombinant

In one aspect the sequence for use in the present invention is a recombinant  
sequence – i.e. a sequence that has been prepared using recombinant DNA  
25 techniques.

These recombinant DNA techniques are within the capabilities of a person of ordinary  
skill in the art. Such techniques are explained in the literature, for example, J.  
Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory*  
30 *Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press.

In one aspect the sequence for use in the present invention is a synthetic sequence –  
i.e. a sequence that has been prepared by *in vitro* chemical or enzymatic synthesis.

It includes, but is not limited to, sequences made with optimal codon usage for host organisms - such as the methylotrophic yeasts *Pichia* and *Hansenula*.

### USE OF ENZYME

5

In one embodiment, the keratin material comprises (or consists of) feathers and the protease is used in range of about 1 g/kg of keratin material to about 10g/kg keratin material.

10 In one embodiment, the keratin material comprises (or consists of) wool, horns, hooves or admixtures thereof and the protease is used in range of about 1 g/kg of keratin material to about 50g/kg keratin material.

It will be understood that one protease unit (PU) is the amount of enzyme that  
15 liberates from the substrate (0.6% casein solution) one microgram of phenolic compound (expressed as tyrosine equivalents) in one minute at pH 7.5 (40mM Na<sub>2</sub>PO<sub>4</sub> / lactic acid buffer) and 40°C. This may be referred to as the assay for determining 1PU.

20 In one embodiment suitably the enzyme as a subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.x.x) and the E.C. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 PU.

25 In one embodiment, the protease is an alkaliphile and optimally hydrolyses at a pH between about pH 7 to about pH 12. Suitably, the protease may optimally hydrolyse at a pH between about pH 8 to about pH 11. Suitably, the protease may optimally hydrolyse at a pH between about pH 8 to about pH 10. Suitably, the protease may optimally hydrolyse at a pH of about 9.

30

In one embodiment, the protease is an acidophile and optimally hydrolyses at a pH between about pH 1 to about pH 7. Suitably, the protease may optimally hydrolyse at

a pH between about pH 3 to about pH 6. Suitably, the protease may optimally hydrolyse at a pH between about pH 4 to about pH 5.

5 In one embodiment, the protease is a neutrophile and optimally hydrolyses at a pH between about pH 6 to about pH 8. Suitably, the protease may optimally hydrolyse at a pH of about 7.

In one embodiment, the protease may hydrolyse optimally at a temperature between about 30°C to about 98°C. Suitably, the protease may hydrolyse optimally at a temperature between about 40°C to about 80°C. Suitably, the protease may  
10 hydrolyse optimally at a temperature between about 50°C to about 80°C. Preferably, the protease may hydrolyse optimally at a temperature between about 60°C to about 80°C.

#### FURTHER COMPONENTS

15

Suitably, the keratin material, protease and non-sulphur containing surfactant may optionally be admixed (simultaneously or sequentially) with one or more further components.

20 Examples of further components include reducing agents, additional enzymes, chemicals, metal ions in the form of a salt, carriers, excipients, diluents, antimicrobials, fats, peptides and minerals.

In one embodiment one or more further components may be selected from the group  
25 consisting of: reducing agents, additional enzymes, antimicrobials, metal ions in the form of a salt, carriers, excipients, diluents, fats, peptides, minerals and combinations thereof

In one embodiment, one or more additional enzyme(s) are added. Said one or more additional enzymes may be selected from the group consisting of esterases, lipases,  
30 cutinases, protein-disulfide reductases (EC 1.8.x.x), metalloproteases, aspartic acid proteases, cysteine proteases, exopeptidases, endoproteases, acyltransferases, perhydrolases, oxidases (e.g. hexose oxidases and maltose oxidoreductases), and proteases.

In one embodiment, one or more one or more metal ions may be used in the form of a salt. Suitably, the metal ion may be one of the group consisting of Cu, Mg, Mn, Co, Zn, Fe and Ca. Suitably, the salt may be a chloride.

5

In one embodiment, an antimicrobial is added as a further component. Suitably, sulphite or its salts are added as an antimicrobial.

### REDUCING AGENT

10

In one aspect, the method and/or uses of the present invention further comprise the use of a reducing agent.

15

The term “reducing agent” as used herein (also referred to as a reductant or reducer) refers to an element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species. Thus a reducing agent will be oxidised in a redox reaction.

20

The presence of a reducing agent may stimulate keratin degradation by a protease. Without wishing to be bound by theory it is thought that reducing agents may breakdown disulphide bonds present in keratin, opening up the structure to aid hydrolysis by a protease.

25

A substance “stimulates” keratin degradation if it increases the speed by which a desired level of keratin degradation is reached and/or if it increases the amount of digestible protein and/or amount of amino acids available after a set time (e.g. 8 hours).

30

Suitably, a reducing agent may be added prior to and/or during the step of reacting keratin material with a protease and a non-sulphur containing surfactant.

In one embodiment, only one reducing agent is used in combination with a protease in the methods and uses of the present invention. In another embodiment, any

combination of two or more reducing agents are used. For example any combination of 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 surfactants may be used.

In one embodiment, one or more reducing agent(s) may be selected from the group  
5 consisting of: salts of sulphite (e.g.  $\text{Na}_2\text{SO}_3$  and  $\text{NaHSO}_3$ ), bisulfite, dithionite metabisulfite DTT,  $\beta$ -mercaptoethanol and sulphide.

Suitably, the reducing agent may be sodium sulphite or sodium bisulphite.

- 10 Whilst one or more reducing agents may be added in the methods and uses of the present invention, the present inventors have surprisingly found that the use of a non-sulphur containing surfactant can reduce the amount of reducing agent used to achieve a desired degree of keratin degradation.
- 15 In one embodiment, the reducing agent may be continuously added during the reaction of the keratin material with a protease and a non-sulphur containing surfactant. Advantageously, continuous addition of a reducing agent during the reaction or a series of additions of the reducing agent (e.g. multiple dosing) during the reaction may result in improved enzymatic hydrolysis. Without wishing to be  
20 bound by theory, it is thought that the reducing agent may be oxidised during the reaction leading to a depletion of reducing agent to break down the disulphide bonds in the keratin material. Therefore, multiple dosing or continuous addition of the reducing agent may allow a more linear reaction of keratin hydrolysis during the enzymatic reaction. Furthermore, multiple dosing and/or continuous addition of the  
25 reducing agent may allow more control over the levels of the reducing agent present at the end of the reaction. This may provide safety advantages as the process can be controlled to ensure lower amounts of the reducing agent in final product. Thus, suitably the reducing agent added may be continuous added or may be added in multiple doses (such as 2 or more times, or 3 or more times, or 4 or more times, or 5  
30 or more times or 10 or more times).

CONTROLLING OXYGEN LEVELS IN THE PROCESS

In the methods of the present invention oxygen levels may be controlled during the step of admixing the keratin material with a protease and a non-sulphur containing surfactant.

In one embodiment, at least the step of admixing a keratin material with a protease and an emulsifier occurs under controlled oxygen levels.

This may be particularly advantageous when a reducing agent is added as a further component. Without wishing to be bound by theory it is thought that by controlling and/or reducing the amount of oxygen available (such as in an open system) the amount of reducing agent may be reduced thereby saving costs and/or providing a safer final product

By "under controlled oxygen levels" it is meant that that the reaction does not have unlimited access to oxygen (such as in an open system). Various means of controlling oxygen levels are known in the art. For example, use of a closed system (e.g. a sealed vessel or reactor) results in a controlled level of oxygen present in the headspace above the reaction solution. Alternatively, means of reducing the level of available oxygen can be employed such as heating the reaction medium, steam flushing, vacuum pumping and/or the addition of nitrogen (e.g. nitrogen bubbling).

In one embodiment, at least the step of reacting a keratin material with a protease and a reducing agent may occur in a closed system (e.g. in a sealed vessel or reactor).

In one aspect, the level of oxygen is controlled such that the oxygen level in the air space of the reactor is less than 50% of the air, preferably less than 30% of the air, preferably less 5% of air in the reactor.

CHEMICAL HYDROLYSIS

In one embodiment of the present invention, the enzymatic hydrolysis of keratin is combined with chemical hydrolysis.

5

Methods for the chemical hydrolysis of keratin are known in the art.

Advantageously, the method of hydrolysing or degrading keratin using a protease and a non-sulphur containing surfactant can result in a reduction of the time and/or amount of chemicals needed using convention chemical hydrolysis methods.

10

The present inventors have surprisingly found that the combination of enzymatic and chemical hydrolysis of keratin can result in a quick and efficient process for keratin degradation.

15

In one aspect the chemical hydrolysis step occurs prior to, during and/or after the reaction step with the protease and non-sulphur containing surfactant.

Suitably, the chemical reaction may occur prior to and/or during step the enzymatic reaction and the chemical oxidant adjusts the pH to a desirable working pH of the protease.

20

In one embodiment, the pH used for the chemical reaction is a pH under which the protease works.

25 In one embodiment, the protease used is an alkaliphile and the chemical oxidant is an alkali. In another embodiment, the protease used is an acidophile and the chemical oxidant is an acid.

Suitably, a chemical (such as an acid, an alkali or oxidant) may be used to chemically hydrolyse keratin. Without wishing to be bound by theory, it is believed that chemical oxidants work by oxidising the disulphide bridges present in keratin which may result in the solubilisation of the keratin. Advantageously, the use of a chemical oxidant

30

may also increase the solubility of the keratin hydrolysate which may provide ease of application to e.g. feed.

5 The term "solubility" as used herein refers to the ability of hydrolysed keratin to dissolve in a solvent (e.g. in water).


The solubility of the keratin hydrolysate can be measured by determining the amount of nitrogen in the supernatant following centrifugation of the reaction mixture.

10 The term "chemical oxidant" as used herein refers to a substance that removes electrons from another reactant in a redox chemical reaction. Chemical oxidants are also referred to as oxidising agents or oxidants.

15 Examples of chemical oxidants which can hydrolyse keratin include sodium chlorite, HCl, acetic acid, hydroxyacetic acid, NaOH, peracids, HOCl, HOBr, NaClO<sub>2</sub>, ClO<sub>2</sub>, H<sub>2</sub>O<sub>2</sub>, ammonium hydroxide, sodium hydroxide, and calcium hydroxide.

20 As used herein the term "a peracid" (also known as a peroxy acid or peroxyacid) is an acid which contains an acidic -OOH group. The two main classes of peracids are those derived from conventional mineral acids, especially sulfuric acid, and the organic derivatives of carboxylic acids. Generally peracids are known to be strong oxidisers.

The general formula of a peracid is shown below:



Suitably the peracid may be peracetic acid or performic acid.

30 Suitably, the chemical may be added to the reaction medium or the chemical may be generated in the reaction medium. For example, peracetic acid may be generated in reaction medium. This can be achieved by the treatment of acetic acid with hydrogen



peroxide using sulfuric acid as the catalyst:  $\text{H}_2\text{O}_2 + \text{CH}_3\text{CO}_2\text{H} \rightleftharpoons \text{CH}_3\text{CO}_3\text{H} + \text{H}_2\text{O}$ . Hydrogen peroxide can be generated enzymatically by for example glucose oxidase and hexose oxidase. Peracetic acid can also be generated by the reaction of triacetin with  $\text{H}_2\text{O}_2$  catalyzed by perhydrolase or aryl esterase.

5

In one embodiment, the chemical may be generated in the reaction medium.

10

The keratin material and chemical are admixed until a desired degree of degradation of the keratin material has occurred (e.g. until the digestibility of keratin material is increased, such as by enriching the concentration of digestible proteins and peptides therein). A person of ordinary skill in the art will readily understand that the optimal time period used will depend on a number of factors such as the temperature and pH used; the degree of cross-linking present in the keratin material to be degraded; and whether other components are used in the process.

15

20

When the enzymatic hydrolysis occurs prior to the chemical hydrolysis, reference to admixing the chemical with "keratin material" refers to admixing the chemical with the resultant material following treatment of keratin material with a protease. Thus, the keratin material which is admixed with the chemical may be partially hydrolysed or degraded. Suitably, the keratin material may be in the form of a precipitate.

25

In one embodiment the chemical is used at a concentration of less than 50 mM, Suitably, the chemical is used at a concentration of less than 40 mM, preferably less than 30mM, preferably less than 20mM. Suitably, the chemical may be used at a concentration of less than 10mM.

30

In one embodiment, the chemical is used at a concentration of between about 0.1 mM to about 49 mM. Suitably, the chemical may be used at a concentration of between about 0.2 mM and about 40mM, preferably at concentration between about 0.5 and about 10mM.

In one embodiment, the keratin material and chemical may be admixed for about 5 minutes to about 24 hours or from about 10 minutes to about 20 hours or from about

15 minutes to about 16 hours or from about 30 minutes to about 10 hours or from about 1 hour to about 8 hours or from about 3 to about 7 hours.

5 In another embodiment, the keratin material and chemical may be admixed for about 30min to 48 hours.

In one embodiment, the keratin material and chemical may be admixed for about 1 hour to about 8 hours.

10 Suitably the keratin material and the chemical may be admixed for at least 5 minutes or at least 10 minutes or at least 15 minutes or at least 20 minutes or at least 25 minutes or at least 30 minutes or at least 45 minutes or at least 1 hour or at least 1.5 hours or at least 2 hours or at least 2.5 hours or at least 3 hours or at least 3.5 hours or at least 4 hours or at least 4.5 hours or at least 5 hours or at least 5.5 hours or at  
15 least 6 hours or at least 7 hours or at least 8 hours or at least 9 hours or at least 10 hours.

In one embodiment, the keratin material and the chemical may be admixed for at least 1 hour.

20

Suitably, the keratin material and the chemical may be admixed for less than 24 hours, or less than 20 hours, or less than 16 hours, or less than 12 hours or less than 10 hours, or less than 8 hours, or less than 6 hours or less than 4 hours, or less than 2 hours or less than 1 hour.

25

In one embodiment, the keratin material and the chemical may be admixed for less than 10 hours.

30 In one embodiment, the keratin material and the chemical oxidant may be admixed until at least 50% by weight of the keratin material is degraded. Suitably, at least 60%, or at least 70%, or at least 80%, or at least 90% or at least 95% or 100% by weight of the keratin material is degraded.

Suitably the pH during the reaction will depend on the chemical used. For example, NaOH works at alkaline pH and HCl at acid pH.

5 Suitably the temperature during the reaction may be adjusted to optimise chemical degradation of the keratin material.

A combination of chemical and enzymatic hydrolysis is not generally used in the commercial production of keratin hydrolysate or the commercial degradation of keratin. This is primarily due to the increased costs associated with this combination.  
10 For example, Kim *et al.* (Poultry Science, 2002, 81:95-98) disclose that a combination of 24 h enzyme treatment and 2-hour chemical treatment were significantly more than double the costs of enzyme treatment or chemical treatment alone.

Advantageously, the present inventors have surprisingly found that enzymatic and  
15 chemical hydrolysis may be combined in a way which significantly reduces the costs typically associated with the combined use of enzymatic and chemical hydrolysis. In one embodiment, when chemical hydrolysis occurs, preferably the chemical hydrolysis step with a chemical occurs at a time point in the process which avoids additional costs associated with the adjustment of the pH for the enzymatic reaction.

20

If the protease is an alkaliphile, preferably the chemical is an alkali and the chemical reaction occurs prior to or simultaneously with the enzymatic reaction. If the protease is an acid, preferably the chemical is an acid and the chemical reaction occurs prior to or simultaneously with the enzymatic reaction. If the protease is an alkaliphile and  
25 the chemical is an acid, preferably, the enzymatic reaction occurs prior to the chemical reaction so that the chemical reaction brings down the pH. If the protease is an acidophile and the chemical is an alkali, preferably, the enzymatic reaction occurs prior to the chemical reaction so that the chemical reaction brings up the pH. In this way, additional costs associated with raising or lowering the pH to optimal conditions  
30 for the protease are avoided.

Suitably, where the chemical hydrolysis step occurs prior to and/or during (e.g. simultaneously with) the reaction with protease, the reaction conditions used are adapted to the working ranges of the protease used.

- 5 In one aspect of the present invention, the chemical used for the chemical hydrolysis also adjusts the pH to the optimal working conditions of the protease, thereby advantageously providing the benefit of combined chemical and enzymatic reactions whilst minimising or avoiding additional costs associated with combining a chemical hydrolysis step with an enzymatic hydrolysis. For example, the protease Protex 30L
- 10 works under high alkaline conditions. Thus, this protease may be combined with an alkali known to chemically hydrolyse keratin such as NaOH. Advantageously, the alkali then works to adjust the pH to the working range of the protease whilst also degrading keratin itself. In this way chemical and enzymatic hydrolysis can be combined in a cost-effective way. Clearly, a protease which works under acidic
- 15 conditions can be combined with an acid known to degrade keratin such as HCl in a similar way.

In one embodiment, the methods of the present invention may use an acidophilic protease. In this embodiment, the methods of the present invention may comprise a

20 chemical hydrolysis step prior to and/or during the reaction with protease, wherein the chemical hydrolysis step uses an acid.

In one embodiment, the methods of the present invention may use an alkaliphilic protease. In this embodiment, the methods of the present invention may comprise a

25 chemical hydrolysis step prior to and/or during the reaction with protease, wherein the chemical hydrolysis step uses an alkali.

Combining chemical hydrolysis with enzymatic hydrolysis may allow for a reduction of the concentration of the chemical used and/or duration which the keratin material is

30 exposed to the chemical may be reduced to achieve a desired level of keratin degradation. Thus, keratin hydrolysate may be produced which advantageously has an enhanced protein digestibility and/or increased source of amino acids compared to the use of either enzymatic or chemical hydrolysis alone.

In one aspect, protein digestibility may be measured by measuring Kjeldahl N content (e.g. in a N autoanalyzer) of the supernatant, following centrifugation of the reaction mixture.

5

In one aspect, “increased source of amino acids” refers to an increase in *in vitro* amino acid digestibility which may be measured in accordance with Kim *et al.* (Poultry Science, 2002, 85:95-98) using the following equation:

$$100 - \frac{\text{amino acid content (g/100g reaction precipitate) of treatment} \times (100 - \text{N solubility of treatment})}{\text{amino acid content (g/100g reaction precipitate) of control} \times (100 - \text{N solubility of control})} \times 100$$

15

In one aspect, the chemical hydrolysis step may occur after the reaction step with a protease. This may be advantageous in situations where the protease selected and the chemical oxidant selected does not work at overlapping pH.

20

## PROCESS FOR PREPARING A FEEDSTUFF

In another aspect there is provided a method for producing animal feed comprising admixing keratin hydrolysate produced by a method of the present invention with one or more animal feed constituents.

25

Advantageously, keratin hydrolysate produced in the accordance with a method of the present invention may provide a valuable source of protein and/or source of amino acids in animal feed. For example, keratin hydrolysate can provide a source of one or more of the following amino acids: methionine, cysteine, lysine, threonine, arginine, isoleucine, leucine, valine, histidine, phenylalanine, glycine, serine, proline, alanine, aspartic acid and glutamic acid.

30

The terms “animal feed” and “feedstuff” are used interchangeably herein. The terms “animal feed constituents” and “feed ingredients” are also used interchangeably.

Animal feed is typically produced in feed mills in which raw materials are first ground to a suitable particle size and then mixed with appropriate additives. The animal feed may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and then the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool. Subsequently liquid additives such as fat and enzyme may be added. Production of the animal may also involve an additional step that includes extrusion or expansion prior to pelleting – in particular by suitable techniques that may include at least the use of steam.

By way of example only animal feed for chickens, e.g. broiler chickens may be comprised of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:

<b>Ingredients</b>	<b>Starter (%)</b>	<b>Finisher (%)</b>
Maize	46.2	46.7
Wheat Middlings	6.7	10.0
Maize DDGS	7.0	7.0
Soyabean Meal 48%CP	32.8	26.2
An/Veg Fat blend	3.0	5.8
L-Lysine HCl	0.3	0.3
DL-methionine	0.3	0.3
L-threonine	0.1	0.1
Salt	0.3	0.4
Limestone	1.1	1.1
Dicalcium Phosphate	1.2	1.2
Poultry Vitamins and Micro-minerals	0.3	0.3

By way of example only the diet specification for chickens, such as broiler chickens, may be as set out in the table below:

<b>Diet specification</b>		
Crude Protein (%)	23.00	20.40
Metabolizable Energy Poultry (kcal/kg)	2950	3100
Calcium (%)	0.85	0.85
Available Phosphorus (%)	0.38	0.38
Sodium (%)	0.18	0.19
Dig. Lysine (%)	1.21	1.07
Dig. Methionine (%)	0.62	0.57
Dig. Methionine + Cysteine (%)	0.86	0.78
Dig. Threonine (%)	0.76	0.68

- 5 By way of example only a feedstuff laying hens may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:

<b>Ingredient</b>	<b>Laying phase (%)</b>
Maize	10.0
Wheat	53.6
Maize DDGS	5.0
Soybean Meal 48%CP	14.9
Wheat Middlings	3.0
Soybean Oil	1.8
L-Lysine HCl	0.2
DL-methionine	0.2
L-threonine	0.1
Salt	0.3
Dicalcium Phosphate	1.6
Limestone	8.9
Poultry Vitamins and Micro-minerals	0.6

By way of example only the diet specification for laying hens may be as set out in the table below:

<b>Diet specification</b>	
Crude Protein (%)	16.10
Metabolizable Energy Poultry (kcal/kg)	2700
Lysine (%)	0.85
Methionine (%)	0.42
Methionine + Cysteine (%)	0.71
Threonine (%)	0.60
Calcium (%)	3.85
Available Phosphorus (%)	0.42
Sodium (%)	0.16

- 5 By way of example only a feedstuff for turkeys may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:

<b>Ingredient</b>	<b>Phase 1 (%)</b>	<b>Phase 2 (%)</b>	<b>Phase 3 (%)</b>	<b>Phase 4 (%)</b>
Wheat	33.6	42.3	52.4	61.6
Maize DDGS	7.0	7.0	7.0	7.0
Soyabean Meal 48%CP	44.6	36.6	27.2	19.2
Rapeseed Meal	4.0	4.0	4.0	4.0
Soyabean Oil	4.4	4.2	3.9	3.6
L-Lysine HCl	0.5	0.5	0.4	0.4
DL-methionine	0.4	0.4	0.3	0.2
L-threonine	0.2	0.2	0.1	0.1
Salt	0.3	0.3	0.3	0.3
Limestone	1.0	1.1	1.1	1.0
Dicalcium Phosphate	3.5	3.0	2.7	2.0
Poultry Vitamins and Micro-minerals	0.4	0.4	0.4	0.4



By way of example only the diet specification for turkeys may be as set out in the table below:

<b>Diet specification</b>				
Crude Protein (%)	29.35	26.37	22.93	20.00
Metabolizable Energy Poultry (kcal/kg)	2.850	2.900	2.950	3.001
Calcium (%)	1.43	1.33	1.22	1.02
Available Phosphorus (%)	0.80	0.71	0.65	0.53
Sodium (%)	0.16	0.17	0.17	0.17
Dig. Lysine (%)	1.77	1.53	1.27	1.04
Dig. Methionine (%)	0.79	0.71	0.62	0.48
Dig. Methionine + Cysteine (%)	1.12	1.02	0.90	0.74
Dig. Threonine (%)	1.03	0.89	0.73	0.59

By way of example only a feedstuff for piglets may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:

<b>Ingredient</b>	<b>Phase 1 (%)</b>	<b>Phase 2 (%)</b>
Maize	20.0	7.0
Wheat	25.9	46.6
Rye	4.0	10.0
Wheat middlings	4.0	4.0
Maize DDGS	6.0	8.0
Soyabean Meal 48% CP	25.7	19.9
Dried Whey	10.0	0.0
Soyabean Oil	1.0	0.7
L-Lysine HCl	0.4	0.5
DL-methionine	0.2	0.2
L-threonine	0.1	0.2
L-tryptophan	0.03	0.04
Limestone	0.6	0.7
Dicalcium Phosphate	1.6	1.6
Swine Vitamins and Micro-minerals	0.2	0.2
Salt	0.2	0.4

By way of example only the diet specification for piglets may be as set out in the table below:

<b>Diet specification</b>		
Crude Protein (%)	21.50	20.00
Swine Digestible Energy (kcal/kg)	3380	3320
Swine Net Energy (kcal/kg)	2270	2230
Calcium (%)	0.80	0.75
Digestible Phosphorus (%)	0.40	0.35
Sodium (%)	0.20	0.20
Dig. Lysine (%)	1.23	1.14
Dig. Methionine (%)	0.49	0.44
Dig. Methionine + Cysteine (%)	0.74	0.68
Dig. Threonine (%)	0.80	0.74

By way of example only a feedstuff for grower/finisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:

<b>Ingredient</b>	<b>Grower/ Finisher (%)</b>
Maize	27.5
Soyabean Meal 48% CP	15.4
Maize DDGS	20.0
Wheat bran	11.1
Rice bran	12.0
Canola seed meal	10.0
Limestone	1.6
Dicalcium phosphate	0.01
Salt	0.4
Swine Vitamins and Micro-minerals	0.3
Lysine-HCl	0.2
Vegetable oil	0.5

By way of example only the diet specification for grower/finisher pigs may be as set out in the table below:

<b>Diet specification</b>	
Crude Protein (%)	22.60
Swine Metabolizable Energy (kcal/kg)	3030
Calcium (%)	0.75
Available Phosphorus (%)	0.29
Digestible Lysine (%)	1.01
Dig. Methionine + Cysteine (%)	0.73
Digestible Threonine (%)	0.66

- 5 Thus, it can be seen that keratin hydrolysate can be used as a good and potentially cheap source of protein and/or amino acids required in these diets.

### FEED

- 10 When used in the feed or in a method of preparing feed, the keratin hydrolysate produced in accordance with the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant or a nutritionally active ingredient.

15

The term “animal feed” as used herein means food suitable for animal consumption, such as for cows, pigs, lamb, sheep, goats, chickens, turkeys, ostriches, pheasants, deer, elk, reindeer, buffalo, bison, antelope, camels, kangaroos; horses, fish; cats, dogs, guinea pigs, rodents e.g. rats, mice, gerbils and chinchillas.

20

The keratin hydrolysate produced in accordance with the present invention may be added to the animal feed or a component in a manner known per se.

- 25 Preferably the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof. In one embodiment keratin hydrolysate produced in accordance with

the present invention may be admixed with, and/or applied onto, a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder.

- 5 The term fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.

The term fodder includes hay, straw, silage, compressed and pelleted feeds, oils and  
10 mixed rations, and also sprouted grains and legumes.

Fodder may be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white  
15 clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy-grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.

- 20 The term "compound feed" means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble. Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.

- 25 Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins.

The main ingredients used in compound feed are the feed grains, which include corn,  
30 soybeans, sorghum, oats, and barley.

Suitably a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, inhibitory

substances, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.

- In the method of preparing an animal feed in accordance with the present invention
- 5 one or more one or more feed materials may be added selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm
- 10 kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins.
- 15 Animal feed produced by the method of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60% by weight corn and soybean meal or corn and full fat soy, or wheat meal or sunflower meal.

- In addition or in the alternative, animal feed produced by a method of the present
- 20 invention may comprise at least one high fibre feed material and/or at least one by-product of the at least one high fibre feed material to provide a high fibre feedstuff. Examples of high fibre feed materials include: wheat, barley, rye, oats, by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm
- 25 kernel, and citrus pulp. Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.

- In the present invention the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: corn,
- 30 soybeans, sorghum, oats, barley, corn stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage;

seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract.

As used herein the term "applied" refers to the indirect or direct application of the  
5 keratin hydrolysate produced in accordance with the present invention to the product (e.g. the feed). Examples of the application methods which may be used, include, but are not limited to, treating the product in a material comprising the keratin hydrolysate, direct application by mixing the keratin hydrolysate with the product, spraying the keratin hydrolysate onto the product surface or dipping the product into  
10 a preparation of the keratin hydrolysate .

In one embodiment the keratin hydrolysate produced by a method of the present invention is preferably admixed with, or applied onto, the product (e.g. feedstuff). Alternatively, the keratin hydrolysate may be included in the emulsion or raw  
15 ingredients of a feedstuff.

As used herein the term "swine" relates to non-ruminant omnivores such as pigs, hogs or boars. Typically, swine feed includes about 50 percent carbohydrate, about 20 percent protein and about 5% fat. An example of a high energy swine feed is  
20 based on corn which is often combined with feed supplements for example, protein, minerals, vitamins and amino acids such as lysine and tryptophan. Examples of swine feeds include animal protein products, marine products, milk products, grain products and plant protein products, all of which may further comprise natural flavourings, artificial flavourings, micro and macro minerals, animal fats, vegetable  
25 fats, vitamins, preservatives or medications such as antibiotics. It is to be understood that where reference is made in the present specification, including the accompanying claims, to 'swine feed' such reference is meant to include "transition" or "starter" feeds (used to wean young swine) and "finishing" or "grower" feeds (used following the transition stage for growth of swine to an age and/or size suitable for  
30 market).

As used herein the term "poultry" relates to fowl such as chickens, broilers, hens, roosters, capons, turkeys, ducks, game fowl, pullets or chicks. Poultry feeds may be

referred to as "complete" feeds because they contain all the protein, energy, vitamins, minerals, and other nutrients necessary for proper growth, egg production, and health of the birds. However, poultry feeds may further comprise vitamins, minerals or medications such as coccidiostats (for example Monensin sodium, Lasalocid, Amprolium, Salinomycin, and Sulfaquinoxaline) and/or antibiotics (for example Penicillin, Bacitracin, Chlortetracycline, and Oxytetracycline).

Young chickens or broilers, turkeys and ducks kept for meat production are fed differently from pullets saved for egg production. Broilers, ducks and turkeys have larger bodies and gain weight more rapidly than do the egg-producing types of chickens. Therefore, these birds are fed diets with higher protein and energy levels.

It is to be understood that where reference is made in the present specification, including the accompanying claims, to "poultry feed" such reference is meant to include "starter" feeds(post-hatching),"finisher","grower" or "developer" feeds (from 6-8 weeks of age until slaughter size reached) and "layer" feeds (fed during egg production).

## PET FOOD

In one aspect, the "animal feed" may be a pet food. The term "pet food" as used herein means a food suitable for consumption by a domesticated animal such as a dog, cat, horse, pig, fish, bird, hamster, gerbil, guinea pig, rodent e.g. rat, mouse, rabbit and chinchilla

The keratin hydrolysate may be applied on, or in, the pet food itself and/or constituent(s) (e.g. ingredients) of the pet food. For example, the keratin hydrolysate may be applied on, or in, a palatant.

Examples of typical constituents found in dog and cat food include palatants, Whole Grain Corn, Soybean Mill Run, Chicken By-Product Meal, Powdered Cellulose, Corn Gluten Meal, Soybean Meal, Chicken Liver Flavor, Soybean Oil, Flaxseed, Caramel Color, Iodized Salt, L-Lysine, Choline Chloride, Potassium Chloride, vitamins (L-



Ascorbyl-2- Polyphosphate (source of vitamin C), Vitamin E Supplement, Niacin, Thiamine Mononitrate, Vitamin A Supplement, Calcium Pantothenate, Biotin, Vitamin B12 Supplement, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Vitamin D3 Supplement), Vitamin E Supplement, minerals (e.g., Ferrous Sulfate, Zinc Oxide, 5 Copper Sulfate, Manganous Oxide, Calcium Iodate, Sodium Selenite), Taurine, L-Carnitine, Glucosamine, Mixed Tocopherols, Beta-Carotene, Rosemary Extract.

A pet food recipe suitable for addition of the keratin hydrolysate of the current invention may be based on the following main ingredients: maize meals (whole, meal, 10 or ground), poultry edible offal meal, wheat bran, alfalfa meal, maize gluten, rice, linseed meal, rapeseed meal, soybean meal or bean meal. Preferably this recipe also contains stabilizers, and is supplemented with various vitamins and antioxidants such as vitamin a, cholecalciferol, vitamin e, menadione, citric acid, pantothenic acid, folic acid, vitamin b12, vitamin b6, riboflavin (vitamin b2), vitamin b1, niacin (vitamin 15 b3), and preferably flavour enhancers such as glutamine, taurine, yeast extract, and salt. Alternatively, or additionally, said recipe may be supplemented with a reconstituted food ingredient such as beef meal, powdered beef bone, chicken fat, chicken liver (hydrolyzed), fish meal or fish powder (such as tuna powder).

20 In one aspect, the pet food may be a wet or dry pet food, which may be in the form of a moist pet food (e.g. comprising 18-35% moisture), semi-moist pet food (e.g. 14 to 18% moisture), dry pet food, pet food supplement or a pet treat. Some pet food forms (e.g. moist and semi-moist pet food) are particularly susceptible to contamination due to the fact that the processing conditions for preparing the pet food are not sufficient 25 to kill all microorganisms on, or in, the pet food.

Suitably, the pet food may be in kibble form.

In one aspect, the pet food may be suitable for a dog or a cat.

30

In one aspect the pet food prepared with said keratin hydrolysate of the current invention may be described as anallergenic if it assists pets that usually experience adverse food reactions to the extent that the animals can be described as having

food allergies or intolerances, and in the worst cases inflammatory bowel disease. A typical anallergeinc pet food composition usually maintains the standard 20% protein composition, which can be in the form of keratin hydrolysate if the pepsin digestability is sufficiently high (ideally greater than 75%), and also contains such innocuous ingredients as corn starch, coconut oil, soybean oil or hydrolysed soy, natural flavours, potassium phosphate, powdered cellulose, calcium carbonate, sodium silico aluminate, chicory, L-tyrosine, fructooligosaccharides, fish oil, L-lysine, choline chloride, taurine, L-tryptophan, vitamins [DL-alpha tocopherol (source of vitamin E), inositol, niacin, L-ascorbyl-2-polyphosphate (source of vitamin C), D-calcium panthotenate, biotin, pyridoxine hydrochloride (vitamin B6), riboflavine (vitamin B2), thiamine mononitrate (vitamin B1), vitamin A acetate, folic acid, vitamin B12 supplement, vitamin D3 supplement], DL-methionine, marigold extract (*Tagetes erecta L.*), histidine, trace minerals [zinc proteinate, zinc oxide, ferrous sulfate, manganese proteinate, copper proteinate, copper sulfate, manganous oxide, calcium iodate, sodium selenite], rosemary extract, preserved with natural mixed tocopherols and citric acid.

In one aspect, the pet food may be fish food. A fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health. Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the colour of ornamental fish.

In one aspect, the pet food may be a bird food. Bird food includes food that is used both in birdfeeders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat).

In one aspect, the keratin hydrolysate may be incorporated within the pet food or on the surface of the pet food, such as, by spraying or precipitation thereon.

In one aspect, the keratin hydrolysate is formulated for use in pet food. In this aspect, the keratin hydrolysate may comprise additional anti-contaminant agents

such as phosphoric acid, propionic acid and propionates, sulfites, benzoic acid and benzoates, nitrites, nitrates and parabens.

Suitably, the keratin hydrolysate may be added to a pet food or constituent thereof  
5 such that the keratin hydrolysate is present at about 0.1% to about 10%, about 0.1 to about 5%, or about 0.1 to about 3% by weight of the pet food. In one aspect the anti-contaminant composition is present at about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0% by weight of the pet food where any of the stated  
10 values can form an upper or lower endpoint when appropriate.

In one aspect, the pet food may be a kibble. An illustrative method of preparing a kibble comprises the following steps:

- a. preconditioning by mixing wet and dry ingredients at elevated temperature to form  
15 a kibble dough;
- b. extruding the kibble dough at a high temperature and pressure;
- c. drying the extruded kibble; and
- d. enrobing or coating the dried kibble with topical liquid and/or dry ingredients.

20 Suitably, the keratin hydrolysate can be applied to the kibble at any stage in the process, such as at step a and/or d.

## FORMS

25 hydrolysate hydrolysate The keratin hydrolysate produced by the method of the present invention may be used in any suitable form – whether when alone or when present in a composition. Said composition may include other nutrition-rich waste streams from slaughter houses such as blood or meat and bone meal, or it may be prepared in a composition with other animal feeds including but not limited to  
30 soybean meal, fish meal, fish oil, whey powder, whey filtrate, distillers grains, cottonseed meal, corn gluten meal, canola meal, and the like.

The dry powder or granules may be prepared by means known to those skilled in the art, such as, in top-spray fluid bed coater, in a bottom spray Wurster or by drum granulation (e.g. High sheer granulation), extrusion, pan coating or in a microingredients mixer.

5

Suitably, the keratin hydrolysate may be provided as a spray-dried or freeze-dried powder. An example of such a spray dried keratin hydrolysate is shown in example 5. Such spray dried powders have the advantages of increased stability and handling compared to forms with a higher water content, but said powders are still able to be provided in solution or suspended form to young animals most in need of nutritional supplement. In one embodiment of the current invention the spray dried keratin hydrolysate is in a powder form especially suitable for feeding young pets and commercial livestock, including but not limited to cows, pigs, mink, dogs, cats, broiler chickens and turkeys. The small particle size of the spray dried keratin hydrolysate also makes it particularly suitable for smaller creatures such as young fish (fry), and crustaceans such as shrimp and crabs.

10

15

In one aspect, the keratin hydrolysate is in a liquid formulation. Such liquid consumption may contain one or more of the following: a buffer, salt, sorbitol and/or glycerol.

20

In one embodiment the keratin hydrolysate of the present invention may be formulated with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch,  $\text{Na}_2\text{SO}_4$ , Talc, PVA, sorbitol, benzoate, sorbate, glycerol, sucrose, propylene glycol, 1,3-propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.

25

### 30 ISOLATED

In one aspect, suitably the enzyme(s) used in the present invention may be in an isolated form. The term "isolated" means that the enzyme is at least substantially

free from at least one other component with which the enzyme is naturally associated in nature and as found in nature. The enzyme of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.

### PURIFIED

In one aspect, preferably the enzyme according to the present invention is in a purified form. The term "purified" means that the enzyme is present at a high level. The enzyme is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.

The invention will now be described, by way of example only, with reference to the following Figures and Examples.

### EXAMPLES

#### EXAMPLE 1

**Materials:** Sodium sulfite (Sigma S0505) and sodium bisulfite (E222)(24,397-3, Sigma-Aldrich) were purchased from Sigma (St Louis, USA), Grindsted® SSL P 55 VEG K-A (E481, Sodium stearyl lactate) and Panodan® 517 KOSHER (E472e diacetyltartaric acid esters of mono- and diglycerides), Protex 6L (127000 units/g) and Protex 30L (48208 units/g) were from Danisco A/S (Brabrand, Denmark).

The reaction mixtures contained 9ml water, 1ml tris-HCl (0.48M, pH8.5), one chicken feather, 150 microliter of Protex 30L and the reducing agent given in Table 1. The reactors of 13ml volume yellow cap tubes were screwed airtight with lock. The reaction was incubated at 50°C with shaking at 100 rpm overnight (13h).

**Table 1**

Tube Id	K1	K2	E0	E1	E2
Sodium sulfite	20mg	-	-	20mg	-
Sodium bisulfite (E222)	-	20mg	-	-	20mg
Protex 30L	-	-	150ul	150ul	150ul

## 5 Results

From Figure 1 one can see that feather with only sodium bisulfite (and sodium sulfite photo not shown) in the air tight system no feather degradation was noticed after 13h at 50°C. There was hydrolysis by Protex 30L in the absence of the sulfites (E0). However, hydrolysis was enhanced in the presence of sodium sulfite (E1) and sodium bisulfite (E2).

## EXAMPLE 2

The reaction mixtures contained 12ml water, 1ml tris-HCl (0.48M, pH8.5), one chicken feather, 150 microliter of Protex 6L and the emulsifier and/or reducing agent as detailed in Table 2 below. The reactors of 13ml volume yellow cap tubes were screwed airtight with lock. The reaction was incubated at 50°C with shaking at 100 rpm overnight (13h). The test-tube simulated a free-fall reactor as during the shaking the feather was moving freely in the tube.

**Table 2.**

Tube Id	1.0	1.1	1.2	1.3	2.0	2.1	2.2	2.3
Grindsted® SSL	20mg	20mg	-	20mg	-	-	-	-
Panodan® 517	-	-	-	-	20mg	20mg	-	20mg
Sodium sulfite	20mg	20mg	20mg	-	20mg	20mg	20mg	-
% Nitrogen in the supernatant	Average = 2.27		1.74	0.90	Average = 2.09		1.96	0.96

**Results:** At the end of the overnight incubation, the tubes were centrifuged and the supernatants were collected for total nitrogen analysis by Kjeldahl method.

- 5 From Figures 2 and 3 it can be seen that both emulsifiers Grindsted® SSL and Panodan® 517 stimulated the chicken feather hydrolysis by Protex 6L in an air tight system. Grindsted® SSL was apparently more efficient than Panodan® 517 (Tube 1.3 vs 2.3) as seen by the amount of precipitate which are the partially hydrolysed feather. The addition of both emulsifiers and sodium sulfite (tube 1.0, 1.1, 2.0, 2.1)
- 10 are more efficient than either sodium sulfite (tube 1.2 and 2.2) or the emulsifier alone (tube 1.3 and 2.3) as visually judge by the amount of precipitate formed and residual feather.

### EXAMPLE 3

15

#### **Materials:**

Incubator-shaker: set at 37°C

ASYS Hitech Multispence (96-channel liquid dispenser)

- 50mM Buffer Tris-HCl (pH8.5) containing 0.005% Tween-80 (emulsifier Tween 80,
- 20 Polysorbate 80, E433).

1mg/mL TNBS solution (Picrylsulfonic Acid Sigma cat.#P5878), Keratin (ICN Biochemical, cat. #902111) which was prepared from hooves and horns.

#### A. Substrate Preparation

- 25 The keratin was prepared in 5mg/mL concentrations using the buffer. 1.5mL substrate was liquated into wells of a 24-well Co-Star plate while the mixture was stirred. Plates were covered with heat-resistant plate sealers. Plates were pre-incubated at 37°C for about 20 minutes prior to enzyme addition.

- 30 B. Enzyme Preparation

Protex P dilution stock plates containing 1000, 500, 250, and 125 ppm starting enzyme concentrations were prepared.

### C. Sample Reaction/Incubation Conditions

Plates containing the substrate solution were pre-incubated for about 20 minutes using the desired temperature prior to enzyme addition. The diluted Protex P was added and the reaction mixture was incubated at 37°C, 150 rpm for 2 hours.

5

### D. TNBS Detection

1 mg/mL TNBS solution (prepared freshly) using Reagent A<sup>1</sup>/<sub>2</sub> was prepared. 60 µL of this solution was aliquoted into a 96-well microtiter plate. Using the multiscanner, 10 µL of the reaction mixture was added and mixed for 20 minutes in a plate shaker at room temperature. Reagent B was added, mixed for 1 minute and the endpoint was read at 405 nm.

10

TNBS Recipe (The 2 reagents below are stable for months):

Reagent A <sup>1</sup>/<sub>2</sub> (1 liter), 2.4g NaOH, 45.4g Na<sub>2</sub>B<sub>4</sub>O<sub>7</sub>·10H<sub>2</sub>O, Dissolved by heating.

15

Reagent B (2 liters), 70.4g NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 1.2g Na<sub>2</sub>SO<sub>3</sub>

**Results:** As can be seen in Figure 4, Protex P was able to hydrolyze keratin in the presence of the food grade emulsifier (Tween 80, E433). The hydrolysis increased with the increase in the concentration of the Protex P.

20

## EXAMPLE 4

### Materials and Methods

Chemicals:

25

Sodium decanoate (>98%), Triton X-100™, Tween 20®, and sodium bisulfite were obtained from Sigma-Aldrich, Switzerland. Panodan®, SSL®, and Protex® P were obtained from DuPont Nutrition Biosciences Denmark, Denmark. All other chemicals used were of analytic grade.

Experimental setup:

30

200 mg of homogenized chicken feather was weighed into 12 mL capped reaction vials. 0.1 % w/v emulsifier (sodium decanoate, Triton X-100™, Tween 20®, Panodan®, or SSL®), 1 % v/v protease (Protex® P), 0.025 mM H<sub>3</sub>BO<sub>3</sub> pH 9.0 reaction buffer, and 0.5 % w/v sodium bisulfite were added to a final reaction volume



of 10 mL. All reaction vials were mixed and placed in an incubator for 20 h at 50 °C, 150 rpm. After 20 hours the vials were centrifuged for 30 min at 4000 rpm. The supernatant was collected and the degree of feather hydrolysis was measured in duplicates as an increase in soluble protein at  $A_{280}$  using a UV/Vis microplate scanning spectrophotometer (model PowerWavex, Bio-TEK Instruments, Inc., Vermont, USA). 1 unit of keratinolytic activity was determined as an increase in  $A_{280}$  of 0,01 after proper controls had been subtracted. All reactions were performed in triplets.

10 A one-way ANOVA was applied to the data followed by a Holm-Sidak pairwise comparison to investigate the effect of emulsifiers on feather hydrolysis, overall significance level  $P = 0,05$  ( $N=6$ , except for Protex P  $N=24$ ). Statistical analysis was performed using SigmaPlot 11.0 software from Systat Software Inc.

## 15 EXAMPLE 5

Feather hydrolysate samples prepared with and without Protex P were centrifuged (10 min, 10.000 x  $g$ ) and two fractions separated. The soluble fraction (the supernatant) contained soluble peptides, and the pellet fraction (the precipitate)  
20 contained insoluble peptides. The pellet fraction was dried in a freeze drier until constant weight, and weighed. The percent of hydrolyzed feather was approximately 60% for the sample including Protex P and approximately 4% for the sample without Protex P, calculated as per equation 1.

25 Equation 1.

$$\text{Hydrolyzed feathers (\%)} = 100 \% - (X1 - X2) / X1 * 100\%$$

$X1$  = Dry matter mass (g) of chicken feather before hydrolysis

$X2$  = Dry matter mass (g) of pellet fraction

30 The supernatant from the Protex P hydrolyzed feathers was filtered through a 355  $\mu\text{m}$  screen. A Büchi B-191 mini-spray dryer was first started up and run at stable conditions with ion exchanged water with parameters as table 3. Once parameters were stable chicken feather hydrolysate was loaded at a feed rate of 30%, and the

resulting white powder product collected. The powder had a very light white appearance with moisture content of approximately 3% as measured on an A&D ML-50 moisture analyzer (105° C drying temperature).

5 **Table 3**

Liquid before spray (°C)	20
Inlet Preset (°C)	150
Inlet Actual (°C)	150
Outlet (°C)	98
Aspirator (%)	100
Pump (%)	30
Atomizing air flow l/h	600
Atomizing air inlet, bar	5
Vacuum(Mbar)	-42

## Results and discussion

- 10 Five non-sulphur containing emulsifiers were investigated for their effect on feather hydrolysis in presence of protease. All five emulsifiers showed a statistically significant increase and hence stimulated the degree of feather hydrolysis compared with the reactions without non-sulphur containing surfactant present, see Fig. 5. The highest positive effect on feather hydrolysis was found to be in presence of 0,1 % w/v sodium decanoate followed by 0,1 % w/v SSL®, 0,1 % w/v Panodan®, 0,1 % w/v Triton X-100™, and 0,1 % w/v Tween 20®, respectively. The five non-sulphur containing surfactants increased the extent of feather hydrolysis by 16-62 % compared to the reaction without emulsifier present, see Table 3 below.
- 15
- 20 These results clearly show the positive effect of adding a non-sulphur containing surfactant together with protease for the hydrolysis of feather, when compared to reaction without emulsifier present. A possible explanation is that the non-sulphur containing surfactants promote the reaction by making the substrate more accessible for the protease e.g. by opening up the structure of the feather substrate.

Experiments with the five emulsifiers in absence of protease showed the non-sulphur containing surfactants do not merely increase the solubility of certain proteins, see Fig. 6. The addition of non-sulphur containing surfactants alone did not cause a noteworthy increase in soluble protein measured in the supernatant. In fact, when comparing the effects of non-sulphur containing surfactants alone, protease alone, and non-sulphur containing surfactants in presence of protease, there is a strong indication of a synergistically effect on the degree of hydrolysis when combining both non-sulphur containing surfactants and protease, Fig. 7. Except for Tween 20®, the remaining four non-sulphur emulsifiers all showed a statistically significant difference when comparing the observed degree of feather hydrolyzation with the calculated data, thus substantiating the strong indication of a synergistical effect of combining non-sulphur non-sulphur containing surfactants with protease.

**Table 4.** Hydrolysis of feather in presence of five different non-sulphur containing surfactants and protease. Protex P: reaction without a non-sulphur containing surfactant present.

Control: reaction with neither a non-sulphur containing surfactant nor a protease present. Relative comparisons based on one-way ANOVA generated means.

Treatment	Relative activity (%)
Triton X-100™	116
Tween 20®	116
Panodan®	127
SSL®	138
Sodium decanoate	162
Protex® P	100
Control	14

## Conclusion

The results presented here clearly show the positive effects of non-sulphur containing surfactants on the degree of feather hydrolysis. All five non-sulphur containing surfactants showed statistical significantly to promote the reaction compared to the

reaction without a non-sulphur containing surfactant present, with a maximum observed increase of 62%. Furthermore, a statistical significant synergistically effect of combining non-sulphur containing surfactants with protease was observed for four of the investigated non-sulphur containing surfactants when comparing the observed values with generated value based on experimental data.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A method of producing keratin hydrolysate comprising the step of:  
5 i) admixing keratin material with a protease and a non-sulphur containing surfactant.
2. A method according to claim 1 wherein step i) occurs under controlled oxygen levels.
- 10 3. A method of degrading keratin wherein a keratin material is admixed with a protease and a non-sulphur containing surfactant.
4. A method according to any one of claims 1 to 3, wherein the surfactant is  
15 selected from one or more of the group consisting of: sodium decanoate; Triton-X-100; Tween 20; Tween 80; lecithin; polyoxyethylene stearate; polyoxyethylene sorbitan monolaurate; polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitan monopalmitate; polyoxyethylene sorbitan monostearate; polyoxyethylene sorbitan tristearate; ammonium phosphatides;  
20 sodium, potassium or calcium salts of fatty acids; magnesium salts of fatty acids; acetic acid esters of mono- and diglycerides of fatty acids; lactic acid esters of mono- and diglycerides of fatty acids; citric acid esters of mono- and diglycerides of fatty acids; mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides;  
25 polyglycerol esters of fatty acids; polyglycerol polyricinoleate; propane-1,2-diol esters of fatty acids; thermally oxidised soya bean oil interacted with mono- and diglycerides of fatty acids; sodium stearyl-2-lactylate; calcium stearyl-2-lactylate; sorbitan monostearate; sorbitan tristearate; sorbitan monolaurate; sorbitan monooleate and sorbitan monopalmitate.
- 30 5. A method according to any one of claims 1 to 4, wherein the surfactant is sodium stearyl-2-lactylate and/or diacetyltartaric acid esters of mono- and diglycerides.

6. A method according to any one of the preceding claims wherein the keratin material is selected from one or more of the group consisting of: feathers, hair, fur, hooves, nails and wool.
- 5 7. A method according to claim 6 wherein the feathers are poultry feathers (e.g. chicken feathers).
8. A method according to any one of the preceding claims wherein the protease is one or more of the following genera selected from the group consisting of:  
10 *Bacillus*, *Aspergillus*, *Serratia* and *Nocardiopsis*.
9. A method according to any one of the preceding claims wherein the protease is from the genus *Bacillus*.
- 15 10. A method according to any one of the preceding claims wherein the protease comprises a polypeptide sequence as defined in any one of SEQ ID NOs: 1 or 2, or a functional fragment or variant thereof, having at least 75% sequence identity to any one of SEQ ID NOs: 1 or 2 over at least 50 amino acid residues.
- 20 11. A method according to any one of to any one of claims 1 to 9 wherein the protease may be transcribed from a nucleic acid sequence encoding a protease with at least 75% identity to either SEQ ID NO3 or SEQ ID NO4 or a nucleic acid sequence capable of hybridizing to the nucleic acid sequence of SEQ ID NO3 or SEQ ID NO4 or the complement thereof under stringent conditions.
- 25 12. A method according to any one of the preceding claims wherein a reducing agent is added prior to or during reaction step i).
13. A method according to any one of the preceding claims wherein the method  
30 comprises a chemical hydrolysis step.
14. A method according to claim 13, wherein the chemical hydrolysis step occurs prior to and/or during reaction step i).

15. A method according to claim 13, wherein the chemical hydrolysis step occurs after reaction step i).
- 5 16. A method of producing animal feed comprising admixing keratin hydrolysate produced by the method of any one of the preceding claims with one or more animal feed constituents.
- 10 17. Use of a composition comprising a non-sulphur containing surfactant to stimulate enzymatic keratin degradation.
18. Use according to claim 17, wherein the composition comprises a protease and wherein the composition is a pharmaceutical product or a cosmetic product.
- 15 19. Use according to claim 17 wherein the enzyme performing the keratin degradation comprises a polypeptide sequence as defined in any one of SEQ ID NOs: 1 or 2, or a functional fragment or variant thereof having at least 75% sequence identity to any one of SEQ ID NOs: 1 or 2 over at least 50 amino acid residues.
- 20 20. Use of keratin hydrolysate produced by the method of any one of claims 1 to 16 in feed.
21. Keratin hydrolysate produced by the method of any one of claims 1 to 16.
- 25 22. A feed additive composition comprising the keratin hydrolysate of claim 21.
23. A feed comprising the keratin hydrolysate of claim 21.
- 30 24. A method as substantially described herein with reference to the Examples and drawings.

25. A use as substantially described herein with reference to the Examples and drawings.

26. A product as substantially described herein with reference to the Examples and drawings.

5



1/6

Fig. 1





Fig. 2




2/6

Fig. 3



Fig. 4



3/6

Fig. 5






Fig. 6



4/6

**Fig. 7****Fig. 8**

Sequence ID NO1:

AQSVP WGISR VQAPA AHNRG LTGSG VKVAV LDTGI STHPD LNIRG GASFV  
 PGEPS TQDGN GHGTH VAGTI AALDN SIGVL GVAPS AELYA VKVLG ASGSG  
 AISSI AQGLE WAGNN GMHVA NLSLG SPSPS ATLEQ AVNSA TSRGV LVVAA  
 SGNSG AGSIS YPARY ANAMA VGATD QNNNR ASFSQ YGAGL DIVAP  
 GNVVQ STYPG STYAS LNGTS MATPH VAGAA ALVKQ KNPSW SNVQI RNHLK  
 NTATS LGSTN LYGSG LVNAE AATR

**Fig. 9**

Sequence ID NO 2

AQTVP YGIPL IKADK VQAQG FKGAN VKVAV LDTGI QASHP DLNVV GGASF  
VAGEA YNTDG NGHGT HVAGT VAALD NTTGV LGVAP SVSLY AVKVL NSSGS  
GSYSG IVSGI EWATT NGMDV INMSL GGASG STAMK QAVDN AYARG VVVVA  
AAGNS GSSGN TNTIG YPAKY DSVIA VGAVD SNSNR ASFSS VGAEL EVMAP  
GAGVY STYPT NTYAT LNGTS MASPH VAGAA ALILS KHPNL SASQV RNRLS  
STATY LGSSF YYGKG LINVE AAAQ

**Fig. 10**

Sequence ID NO 3

GCGCAAACCGTTCCTTACGGCATTCTCTCATTAAAGCGGACAAAGTGCAGG  
CTCAAGGCTTTAAGGGAGCGAATGTAAAAGTAGCCGTCCTGGATACAGGAAT  
CCAAGCTTCTCATCCGGACTTGAACGTAGTCGGCGGAGCAAGCTTTGTGGCT  
GGCGAAGCTTATAACACCGACGGCAACGGACACGGCACACATGTTGCCGGT  
ACAGTAGCTGCGCTTGACAATAACGGGTGTATTAGGCGTTGCGCCAAGCG  
TATCCTTGACGCGGTAAAGTACTGAATTCAAGCGGAAGCGGATCATACAG  
CGGCATTGTAAGCGGAATCGAGTGGGCGACAACAAACGGCATGGATGTTATC  
AATATGAGCCTTGGGGGAGCATCAGGCTCGACAGCGATGAAACAGGCAGTC  
GACAATGCATATGCAAGAGGGGTTGTCGTTGTAGCTGCAGCAGGGAACAGC  
GGATCTTCAGGAAACACGAATACAATTGGCTATCCTGCGAAATACGATTCTGT  
CATCGCTGTTGGCGCGGTAGACTCTAACAGCAACAGAGCTTCATTTTCCAGT  
GTGGGAGCAGAGCTTGAAGTCATGGCTCCTGGCGCAGGCGTATACAGCACT  
TACCCAACGAACACTTATGCAACATTGAACGGAACGTCAATGGCTTCTCCTCA  
TGTAGCGGGAGCAGCAGCTTTGATCTTGTCAAAACATCCGAACCTTTAGCTT  
CACAAGTCCGCAACCGTCTCTCCAGCACGGCGACTTATTTGGGAAGCTCCTT  
CTACTATGGGAAAGGTCTGATCAATGTCTGAAGCTGCCGCTCAA

**Fig. 11**

Sequence ID NO 4

GCGCAGTCCGTGCCTTACGGCGTATCACAAATTAAAGCCCCTGCTCTGCACTC  
TCAAGGCTACACTGGATCAAATGTAAAGTAGCGGTTATCGACAGCGGTATCG  
ATTCTTCTCATCCTGATTTAAAGGTAGCAGGCGGAGCCAGCATGGTTCCTTCT  
GAAACAAATCCTTTCCAAGACAACAACCTCTCACGGAACCTCACGTTGCCGGCA  
CAGTTGCGGCTCTTAATAACTCAATCGGTGTATTAGGCGTTGCGCCAAGCGCA  
TCACTTTACGCTGTAAAAGTTCTCGGTGCTGACGGTTCCGGCCAATACAGCTG  
GATCATTAACGGAATCGAGTGGGCGATCGCAAACAATATGGACGTTATTAACAT  
GAGCCTCGGCGGACCTTCTGGTTCTGCTGCTTTAAAAGCGGCAGTTGATAAA  
GCCGTTGCATCCGGCGTCGTAGTCGTTGCGGCAGCCGGTAACGAAGGCACT  
TCCGGCAGCTCAAGCACAGTGGGCTACCCTGGTAAATACCCTTCTGTCATTGC  
AGTAGGCGCTGTTGACAGCAGCAACCAAAGAGCATCTTTCTCAAGCGTAGGA  
CCTGAGCTTGATGTCATGGCACCTGGCGTATCTATCCAAAGCACGCTTCCTGG  
AAACAAATACGGCGCGTTGAACGGTACATCAATGGCATCTCCGCACGTTGCCG  
GAGCGGCTGCTTTGATTCTTTCTAAGCACCCGAACTGGACAAACACTCAAGTC  
CGCAGCAGTTTAGAAAACACCACTACAAAACCTTGGTGATTCTTTCTACTATGGA  
AAAGGGCTGATCAACGTACAGGCGGCAGCTCAG

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2013/065362

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A23K1/10 C12P21/06  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A23K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, COMPENDEX, EMBASE, FSTA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RINKY RAJPUT ET AL: "Biochemical Characterization of a Thiol-Activated, Oxidation Stable Keratinase from Bacillus pumilus KS12", ENZYME RESEARCH, ARTICLE NO. 132148, vol. 2010, 16 June 2010 (2010-06-16), pages 1-7, XP055087923, DOI: 10.4061/2010/132148 abstract; figure 6; tables 2, 3 paragraphs [03.5], [03.6], [03.7] ----- -/--	1,3,4, 6-9, 12-14, 16-18, 20-23



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 November 2013

Date of mailing of the international search report

27/11/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Schröder, Gunnar

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/065362

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RINKY RAJPUT ET AL: "Cloning and characterization of a thermostable detergent-compatible recombinant keratinase from <i>Bacillus pumilus</i> KS12", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 58, no. 2, 19 April 2011 (2011-04-19), pages 109-118, XP055087922, DOI: 10.1002/bab.16 abstract; tables 2, 3 paragraphs [3.3.] - [3.6.] -----	1,3,4, 6-9, 12-14, 16-18, 20-23
X	DAROIT DANIEL J ET AL: "Characterization of a keratinolytic protease produced by the feather-degrading Amazonian bacterium <i>Bacillus</i> sp. P45", BIOCATALYSIS AND BIOTRANSFORMATION, vol. 28, no. 5-6, December 2010 (2010-12), pages 370-379, XP008165823, abstract page 372, right-hand column, paragraph 3 - page 373, left-hand column, paragraph 2; tables III, V page 375, right-hand column, paragraphs 3, 1 page 377, right-hand column, lines 10-23 -----	1,3,4, 6-9, 12-14, 16-18, 20-23
X	DATABASE WPI Week 200537 Thomson Scientific, London, GB; AN 2005-359273 XP002716407, & JP 2005 120286 A (LITTLE SCIENTIST KK) 12 May 2005 (2005-05-12) abstract -----	1,3,4, 6-15, 17-19,21
X	JAOUADI B ET AL: "Purification and characterization of a thermostable keratinolytic serine alkaline proteinase from <i>Streptomyces</i> sp. strain AB1 with high stability in organic solvents", BIORESOURCE TECHNOLOGY, ELSEVIER BV, GB, vol. 101, no. 21, 1 November 2010 (2010-11-01), pages 8361-8369, XP027134551, ISSN: 0960-8524 [retrieved on 2010-06-17] abstract; table 6 paragraphs [3.9.] - [3.11.] ----- -/--	1,3,4,6, 7,16-18, 20-23



## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/065362

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ASHIS K MUKHERJEE ET AL: "Biodegradation of waste chicken-feathers by an alkaline -keratinase (Mukartinase) purified from a mutant sp. strain AS-S10-II", INTERNATIONAL BIODETERIORATION AND BIODEGRADATION, ELSEVIER LTD, GB, vol. 65, no. 8, 6 September 2011 (2011-09-06), pages 1229-1237, XP028106905, ISSN: 0964-8305, DOI: 10.1016/J.IBID.2011.09.007 [retrieved on 2011-10-04] abstract; table 3 paragraphs [3.4.] - [3.5.] page 1236, left-hand column, paragraph 3-4 -----	1,3,4,6, 7,16-18, 20-23
X	WO 02/077187 A2 (GENENCOR INT [US]; PROCTER & GAMBLE [US]; ESTELL DAVID A [US]; GANSHAW) 3 October 2002 (2002-10-03) page 4, lines 11-20 page 65; example 11 -----	1,3,4, 8-11, 17-19,21
X,P	WO 2013/070798 A2 (MARS INC [US]) 16 May 2013 (2013-05-16)  abstract; claims 1, 5, 8 paragraph [0065] -----	1,3,4, 6-14,16, 17,19-23
A	ADRIANO BRANDELLI ET AL: "Biochemical features of microbial keratinases and their production and applications", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 85, no. 6, 29 December 2009 (2009-12-29), pages 1735-1750, XP019778631, ISSN: 1432-0614 the whole document -----	1-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/065362

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 2005120286	A	12-05-2005	NONE	
WO 02077187	A2	03-10-2002	AT 527276 T	15-10-2011
			AU 2002254374 A1	08-10-2002
			CA 2441595 A1	03-10-2002
			CN 1512998 A	14-07-2004
			DK 1373296 T3	09-01-2012
			EP 1373296 A2	02-01-2004
			HK 1061566 A1	10-08-2012
			PL 364138 A1	13-12-2004
			RU 2311458 C2	27-11-2007
			US 2003118605 A1	26-06-2003
			US 2005202551 A1	15-09-2005
			US 2005202552 A1	15-09-2005
			WO 02077187 A2	03-10-2002
WO 2013070798	A2	16-05-2013	US 2013209611 A1	15-08-2013
			WO 2013070798 A2	16-05-2013

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2013/065362

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. (means)
- ☐ on paper
- ☒ in electronic form
- b. (time)
- ☒ in the international application as filed
- ☐ together with the international application in electronic form
- ☐ subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2013/065362

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 24-26  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.2

Claims Nos.: 24-26

Claims 24-26 contain a reference to the description (examples) and drawings. According to Rule 6.2(a) PCT, claims should not contain such references except where absolutely necessary, which is not the case here. In addition, the scope of the subject-matter encompassed by these claim is unclear (Art. 6 PCT) to such an extent that no meaningful search is possible.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guidelines C-IV, 7.2), should the problems which led to the Article 17(2) declaration be overcome.